Aviva Insurance Limited

Solvency and Financial Condition Report Year ended 31 December 2019



Contents

Sur	nr	na	n
Sur	III	Пd	Гy

- Business and Performance А
- В System of Governance
- С **Risk Profile**
- Valuation for Solvency Purposes D
- Е Capital Management
- F Appendices
- F.0 **Cautionary Statement**
- F.1 Public Disclosure Quantitative Reporting Templates
- F.1.1 S.02.01 Balance Sheet
- F.1.2.1 S.05.01 Premium claims and expenses (by line of business) [life]
- F.1.2.2 S.05.01 Premium claims and expenses (by line of business) [non-life]
- F.1.2.3 S.05.02 Premium claims and expenses (by country) [life]
- S.05.02 Premium claims and expenses (by country) [non-life] F.1.2.4
- F.1.3.1 S.12.01 Technical Provisions [life]
- S.17.01 Technical Provisions [non-life] F.1.3.2 S.19.01 Insurance claims [non-life]
- F.1.4 F.1.5 S.22.01 Impact of transitional measures
- F.1.6 S.23.01 Own Funds
- S.25.02 Solvency Capital Requirement F.1.7
- S.28.01 Minimum Capital Requirement F.1.8
- Glossary of Abbreviations and Definitions Directors' Statement F.2
- F.3
- Auditors' Report F.4
- F.5 Additional information on the COVID-19 global pandemic

Aviva Insurance Limited

Solvency and Financial Condition Report 2019

Summary

The purpose of the Solvency and Financial Condition Report (SFCR) is to provide information required by the Solvency II (SII) regulatory framework and in particular the capital position of Aviva Insurance Limited (the Company) at 31 December 2019. The report sets out different aspects of the Company's business and performance, system of governance, risk profile, valuation methods used for solvency purposes and its capital management practices.

On 11 March 2020, the World Health Organization declared the outbreak of a strain of novel coronavirus disease, COVID-19, a global pandemic. Figures presented in the SFCR and the associated Quantitative Reporting Templates (QRTs) have been prepared based on conditions and best estimate assumptions at 31 December 2019 and have therefore not been adjusted for any impacts of COVID-19 including any impacts on technical provisions. On 23 March 2020 the PRA announced that COVID-19 should be treated as a "major development" as per Article 54(1) of the Solvency II Directive. Further information on the impact of COVID-19 on the relevance of information disclosed in the SFCR is contained in section F.5.

Business and Performance

The Company is a limited company registered in Scotland and a member of the Aviva plc group of companies. The Company transacts general and health insurance business in the United Kingdom (UK). The major classes of business underwritten are personal lines (motor, home, creditor and other), health and commercial lines (property, liability, motor and other).

On 1 February 2019, an insurance portfolio transfer of a subset of the Company's business was made to the Company's wholly owned subsidiary Aviva Insurance Ireland Designated Activity Company (AIIDAC), which is incorporated in Ireland. Following the transfer, the Company entered into a quota share reinsurance agreement with AIIDAC, which broadly reinsures 85% of the transferred Ireland branch risks and 100% of other business transferred. Further detail on these transactions is included in section A.1.2 of this report

The Company made an IFRS profit before tax of £221m in the year ended 31 December 2019 (2018: £287m). This comprised underwriting profit of £31m (2018 restated: £120m), net investment income of £309m (2018: £165m) and other costs of £119m (2018 restated: other income of £2m).

The Company's underwriting profit, net investment income and other costs measure the Company's own performance. The performance of the Company's subsidiaries, including its principal subsidiaries Aviva Canada Inc. (ACI) and AIIDAC are not reflected in these measurements, except that dividends received from subsidiaries are included in the Company's net investment income.

Net written premiums, excluding the initial impact of the entering into the quota share reinsurance arrangement with AIIDAC, are broadly stable with growth in the UK offset by the impact of transfer of the Ireland branch business to AIIDAC. The reduction in underwriting profit includes the impact of aligning elements of the UK digital business into the Company, partially offset by improved weather.

The Company has a 50% quota share reinsurance arrangement with fellow subsidiary Aviva International Insurance Limited (AIIL) and ceded net underwriting profit of £69m (2018 restated: £125m) to AIIL during the year.

The other costs incurred during the year ended 31 December 2019 include net costs recharged to the Company in respect of closed defined benefit pension schemes of £29m (2018: £35m), impairment losses on the valuation of subsidiaries, following the receipt of dividends by the Company, of £103m (2018: £46m), foreign exchange gains of £45m (2018: losses of £12m), and the impact of the increase in the Ogden discount rate of £23m (2018: credit of £95m).

Following the announcement of the Lord Chancellor on 15 July 2019 to increase the Ogden discount rate from the minus 0.75% set in 2017 to minus 0.25%, balance sheet reserves were calculated using a discount rate of minus

0.25% at 31 December 2019 (0.00% at 31 December 2018). This has resulted in a strengthening of claims reserves of £23m (net of reinsurance). The Ogden discount rate is expected to be reviewed by the Lord Chancellor within five years.

Section A of this report sets out further details about the Company's key operations and financial performance over the year.

System of Governance

The Board's role is to be collectively responsible for promoting the long-term success of the Company and for setting the Company's strategy, against which management's performance is monitored. It sets the Company's risk appetite and satisfies itself that financial controls and risk management systems are robust, whilst ensuring the Company is adequately resourced. A strong system of governance throughout the Company aids effective decision-making and supports the achievement of the Company's objectives for the benefit of customers and shareholders whilst maintaining compliance with regulations.

Roles and responsibilities for risk management in the Company are based around the 'three lines of defence model' where ownership for risk is taken at all levels in the Company. Line management in the business is accountable for risk management, including the implementation of the Risk Management Framework and embedding of the risk culture.

The Risk Management Framework is embedded throughout the Company and forms an integral part of the management and Board processes and decision-making framework across the Company. The key elements of the Risk Management Framework comprise:

- Risk appetite;
- Risk governance, including risk policies and business standards, risk oversight committees and roles and responsibilities; and
- The processes used to identify, measure, manage, monitor and report (IMMMR) risks, including the use of risk models and stress and scenario testing.

The Risk Committee, on behalf of the Board, last carried out a full review of the effectiveness of the Company's systems of internal control and risk management in March 2020.

During the year, Aviva adopted an organisational model whereby the General Insurance business is now managed separately from Aviva's other UK businesses. In line with this change, the Company has appointed a new Chief Executive Officer (CEO), Chief Financial Officer (CFO), Chief Risk Officer (CRO) and Chief Compliance & Conduct Officer (CCCO). Notwithstanding this change, the Company's Board and Board Committee responsibilities and arrangements, and the fundamental approach to the system of governance, have not materially changed.

There have been no other material changes in the Company's system of governance during the year.

Section B of this report provides further details of the Company's System of Governance.

Risk Profile

The types of risk to which the Company is exposed have not changed significantly over the year and remain credit, market, underwriting, liquidity and operational risks. The Company's risk profile looks through to the underlying risk exposures of its subsidiaries, including ACI and AIIDAC.

Risk identification is carried out on a regular basis, is embedded in the business planning process and any major business initiatives and draws on a combination of internal and external data, covering both normal conditions and stressed environments.

The SII Capital Requirement (SCR) and SII Cover Ratio are the bases on which the Company sets SII capital risk appetites and limits and are used to assess the significance of risks and to appropriately direct resources to their management.

Some categories of risk are not measured and managed solely by holding capital, principally liquidity risk, which is measured through both absolute level targets and bespoke liquidity coverage ratios.

The Company's underlying risk profile has remained relatively stable during the year, although the Company's exposure to underwriting risk has reduced, following ACI entering into a 25% quota share arrangement with AIIL on 1 January 2019.

Section C of this report further describes the risks to which the Company is exposed and how it measures, monitors, manages and mitigates these risks, including any changes in the year to the Company's risk exposures and specific risk mitigation actions taken.

Valuation for Solvency Purposes

Assets, technical provisions and other liabilities are valued in the Company's SII Balance Sheet according to the SII Directive and related guidance. The principle that underlies the valuation methodology for SII purposes is the amount for which they could be exchanged, transferred or settled by knowledgeable and willing third parties in an arm's length transaction.

At 31 December 2019, the Company's excess of assets over liabilities was £1,861m on a SII basis which is £783m lower than the value under IFRS. The difference is driven by the different bases used to value the Company's participations in its subsidiaries, including ACI and AIIDAC, and the elimination of intangibles. Under SII, participations are valued at the Company's proportionate equity share of the excess of assets over liabilities of each subsidiary, valued on a look through basis to the SII value of the assets and liabilities of the entity. Intangibles are valued at nil under SII.

The majority of the Company's assets measured at fair value are based on quoted market information or observable active market data. Where the quoted market information or observable market data is not available, an alternative method for valuation is used.

The Company adopted IFRS 16 Leases on 1 January 2019. The adoption of IFRS 16 resulted in recognition of additional assets of £68m and additional liabilities of £106m. The net impact was treated as a reduction in retained earnings at 1 January 2019. There was no impact on the Company's excess of assets over liabilities on a SII basis as right to use assets equalled lease liabilities. No other material changes were made to the bases used to recognise and value the Company's assets, technical provisions and other liabilities, or to their estimations, during the year.

Section D of this report provides further description of the bases, methods and main assumptions used in the valuation of assets, technical provisions and other liabilities for each material asset or liability class. In addition, it also provides an explanation of the material differences between the IFRS and SII bases of valuation.

Capital Management

The Company's primary capital management objective is to maintain an efficient capital structure in a manner consistent with the Company's risk profile whilst maintaining its regulatory capital surplus in accordance with approved risk appetites.

There have been no material changes to the Company's objectives, policies or processes for managing its capital during the year.

The Company manages its Own Funds in conjunction with its SCR and seeks, on a consistent basis, to:

- Match the profile of its assets and liabilities, taking into account the risks inherent in the business;
- Maintain sufficient, but not excessive, financial strength to support new business growth, and satisfy the requirements of the Company's policyholders and its regulator;
- Retain financial flexibility by maintaining strong liquidity; and
- Allocate capital efficiently, applying it to support value-adding growth and repatriating excess capital to its shareholder through dividends.

In the calculation of the SCR, the Company has chosen to implement a partial internal model (PIM), defined as using a combination of internal model (IM) and standard formula (SF) approaches to calculate solvency capital requirements for different components of its business.

At 31 December 2019, the total eligible Own Funds to meet the SCR was £2,140m (2018: £1,989m). This was represented by £1,790m unrestricted tier 1 capital, £279m tier 2 capital and £71m tier 3 capital, (2018: £1,636m, £276m and £77m respectively).

Total eligible Own Funds to meet the Minimum Capital Requirement (MCR) were £1,873m (2018: £1,710m). This was represented by £1,790m unrestricted tier 1 capital and £83m tier 2 capital, (2018: £1,636m and £74m respectively).

The Company's SCR, at 31 December 2019, was £1,148m (2018: £1,258m). Its MCR was £416m (2018: £368m).

The surplus of eligible Own Funds to SCR was £992m (2018: £731m) which translates to an SII Cover Ratio of 186% (2018: 158%). The increase in the overall surplus position was driven by capital generated from the Company's operations and a reduction in underwriting risk. On 12 February 2020, the directors declared interim dividends of £224m on the Company's ordinary shares, of which £182m was settled in cash and £42m was set-off against accrued interest due on the Company's loan to AGH. This dividend has broadly reduced the Company's SII capital surplus to the 2018 level.

Section E of this report further describes the objectives, policies and procedures employed by the Company for managing its Own Funds. The section also covers information on structure and quality of Own Funds and calculation of SCR, including information about the Company's PIM.

Aviva Insurance Limited

Solvency and Financial Condition Report 2019

A. Business and Performance

In this Chapter

- A.1 Business
- A.2 Underwriting Performance
- A.3 Investment Performance
- A.4 Performance of Other Activities
- A.5 Any Other Information

A. Business and Performance

The 'Business and Performance' section of the report sets out the Company's business structure, key operations, and financial performance over the reporting period.

A.1 Business

The Company is a limited company, registered in Scotland, and is a member of the Aviva plc group of companies (the Group).

Qualifying holdings

The Company's shares and the associated voting rights are wholly owned by Aviva Group Holdings Limited (AGH), being a qualifying holding in the Company.

Supervisor

The Company is authorised by the Prudential Regulatory Authority (PRA). The Company and the Group are regulated by the PRA and the Financial Conduct Authority (FCA) in the UK. The PRA is part of the Bank of England. Contact details for the PRA are as follows:

Address	20 Moorgate, London, EC2R 6DA
Telephone number	+44 (0) 20 7601 4444

External auditor

The Company's external auditor is PricewaterhouseCoopers LLP. Contact details are as follows:

Address	7 More London Riverside, London, SE1 2RT
Telephone number	+44 (0) 20 7583 5000


Financial statements

The Company's financial statements are available from the Company Secretary, Aviva Company Secretarial Services Limited, St Helen's, Undershaft, London, EC3P 3DQ.

The SFCR is presented in pound sterling rounded to the nearest million which is consistent with the presentation in the financial statements, prepared under International Financial Reporting Standards (IFRS). The Quantitative Reporting Templates (QRT) are presented in pound sterling rounded to the nearest thousand. Rounding differences of +/- one unit can occur.

A.1.1 Organisation

The following chart shows, in simplified form, the Company's position within the structure of the Group as at 31 December 2019:



AGH is the immediate parent entity of the Company and Aviva plc is the ultimate controlling parent entity, both are registered in England and Wales. The chart above also presents the Company's material subsidiaries as at 31 December 2019. The Company's material subsidiaries are wholly owned by the Company. A complete list of the Company's subsidiaries and associates is provided in note 37 to the financial statements.

A.1.2 Business operations and events occurring in the year

Business operations

The Company transacts general and health insurance business in the UK. The major classes of business underwritten are personal lines (motor, home, creditor and other), health and commercial lines (property, liability, motor and other). Whilst the Company only conducts non-life insurance activities, the Company has material obligations, similar in nature to life insurance, in the UK in relation to annuities stemming from non-life insurance contracts also known as Periodic Payment Orders (PPO).

Significant business and other events

On 7 December 2018 the Company approved the transfer of a subset of the Company's general insurance business to the Company's subsidiary, AIIDAC, under a Scheme transfer of the Financial Services and Markets Act 2000. The UK Court approved the Scheme on 22 January 2019 and on 1 February 2019 the transfer of the subset of the Company's business to AIIDAC came into effect.

The consideration payable by the Company to AIIDAC under the scheme was £802m, which comprised £625m for the total net liabilities transferred and £177m for capital contributed by the Company to AIIDAC. The Company received ordinary shares with a nominal value of \in 15m, issued by AIIDAC to the Company, in part consideration for the capital contribution. The capital contribution of £177m is shown as an addition to the Company's investment in subsidiaries.

On 1 February 2019, following the Scheme transfer, the Company entered into a quota share reinsurance arrangement with AIIDAC in consideration of a premium of £807m receivable by the Company from AIIDAC. This agreement provides proportional reinsurance to AIIDAC as follows:

- 85% quota share arrangement in respect of the transferring Ireland general insurance branch risks that are situated in the European Economic Area (excluding the UK) and European Mobile Device Insurance (MDI) business; and
- 100% quota share arrangement covering all other transferring business.

In June 2019 the Company acquired a further 10 million ordinary shares of €1 each in AIIDAC, at nominal value, for €10m.

Following the announcement of the Lord Chancellor on 15 July 2019 to increase the Ogden discount rate from the minus 0.75% set in 2017 to minus 0.25%, balance sheet reserves were calculated using a discount rate of minus 0.25% at 31

December 2019 (0.00% at 31 December 2018). This has resulted in a strengthening of claims reserves of £23m (net of reinsurance). The Ogden discount rate is expected to be reviewed by the Lord Chancellor within five years.

The Company increased its ownership of Aviva UK Digital Limited (UKD) from 28% on 31 December 2018 to 31% in February 2019 and then to 100% in December 2019, by way of a capital contribution. The total investment in UKD in the year was £258m. UKD is an insurance intermediary for the Company's direct-to-customer offering.

Dividends of £359m were paid in February 2019 and a further £80m in August 2019. The dividend of £359m was approved by the Board in December 2018 and under SII regulations required to be deducted from Own Funds as a foreseeable dividend as at 31 December 2018.

During the year, the balance of the Company's loan to its immediate parent company, AGH, has reduced by £51m from £1,319m at 31 December 2018 to £1,268m at 31 December 2019. The reduction was settled via an annual repayment in cash of £50m and a transfer from AGH to the Company of shares in the Company's subsidiary Neos Ventures Ltd at their cost of £1m.

A.2 Underwriting Performance

A.2.1 Measurement of underwriting performance

The Company uses underwriting result to measure its underwriting performance. Underwriting result is a non-GAAP financial performance measure, calculated on an IFRS basis. It excludes certain items to enhance comparability and understanding of underwriting performance by highlighting net underwriting income attributable to on-going underwriting operations. Examples of items excluded from underwriting result are investment return and pension costs. The Company's investment performance and its performance of other activities, are detailed in sections A.3 and A.4 respectively.

A.2.2 Underwriting profit

The table below presents the underwriting profit for the Company for the year ended 31 December 2019, as well as the reconciliation of underwriting profit to the profit before tax. The profit before tax is as shown in the Company's financial statements.

	£m	£m	£m	£m
Year ended 31 December	2019	2019	2018	2018
Gross written premiums		6,276		5,421
Premiums ceded to reinsurers		(3,219)		(2,871)
Premiums written net of reinsurance		3,057		2,550
Net change in provision for unearned premiums		(250)		(33)
Net earned premiums		2,807		2,517
Fee and commission income, net of reinsurance		18		20
Net investment income		309		165
Income		3,134		2,702
Claims paid net of recoveries from reinsurers		(1,205)		(1,670)
Change in insurance liabilities, net of reinsurance		(768)		162
Fee and commission expense, net of reinsurance		(682)		(657)
Other expenses, net of reinsurance		(258)		(250)
Profit for the year before tax		221		287
Less: Net investment income (above, see A.3)		(309)		(165)
Add back:				
Changes in economic assumptions for claims	13		3	
provisions				
Net pension costs recharged to the Company for				
closed defined benefit schemes	29		35	
Impairment losses on investment in subsidiaries	103		46	
Impact on claims provisions, net of all reinsurance, of				
the change in the Ogden discount rate	23		(95)	
Foreign exchange gains/(losses)	(45)		12	
Other	(4)		(3)	
Performance of other activities (see A.4) (restated ¹)		119		(2)
Underwriting profit (restated ¹)		31		120

1. Consistent with the treatment adopted in the Group, the Company's underwriting profit for 2018 has been restated from £136m to £120m to include net amortisation costs of £16m, previously included within Performance of other activities.

As noted in section A.1.2, on 1 February 2019 the Company entered into a quota share reinsurance arrangement with AIIDAC in consideration of a premium of £807m. The impact this has had on premiums, the change in provision for unearned premiums and insurance liabilities, and fee and commission expense shown in the above table, is detailed below, excluding the effect of the Company's existing 50% quota share arrangement with AIIL.

Year ended 31 December 2019	£m
Gross written premiums	807
Net change in provision for unearned premiums	(199)
Change in insurance liabilities, net of reinsurance	(636)
Fee and commission expense, net of reinsurance	28
Net impact on underwriting profit	-

The Company's net written premiums, excluding the initial impact of the entering into the quota share reinsurance arrangement with AIIDAC, are broadly stable with 1% growth in UK general insurance and 2% growth in UK Health offset by the impact of the transfer of the Ireland branch business to AIIDAC. The increase in the UK has been driven by continued solid growth in Commercial Lines, in particular in non-motor (within fire and other damage to property and

general liability), across both Small & Medium Enterprises (SME) and Global Corporate & Specialty (GCS) businesses, while UK personal lines premiums have reduced, notably in the Direct and Broker markets, reflecting pricing discipline and targeted reductions in poor performing segments, offset by continued growth in Aggregator and Strategic Partners.

Underwriting profit

The Company's underwriting profit of £31m (2018 restated¹: £120m) is net of underwriting profit ceded to AIIL during the year of £69m (2018 restated: £125m) under the 50% quota share arrangement.

Underwriting profit of £20m (2018 restated: £105m) arose in the UK and £11m (2018 restated: £15m) in Ireland.

The UK underwriting profit reduction includes the impact of aligning elements of the UK digital business into the Company, including increased commission payments to cover the extent of expenses incurred by UKD related to general insurance, as well as increased investment in IT infrastructure, which was partially offset by improved weather experience compared to 2018 (within fire and other damage to property). The Ireland result reflects lower premiums and the impact of increased motor levies.

A.2.3 Quantitative Reporting Templates S.05.01

Quantification of premiums, claims and expenses, analysed by SII lines of business, is provided in QRT S.05.01, (see Appendix F.1.2.1 and F.1.2.2). These QRT have been prepared in accordance with the definitions and formats prescribed under SII. They include the items (except net investment income) excluded from underwriting result in the reconciliation presented in section A.2.2 which are described in section A.4.

A summary of the information provided in the premium, claims and expenses QRT S.05.01, analysed by SII lines of business, is provided in the tables below.

£m	Medical expense	Motor vehicle liability	Other motor	Fire and other	General liability	Annuities stemming	Other SII lines of	Tota
	insurance	insurance	insurance	damage to property insurance	insurance	from non- life contracts	business	
Year ended 31 December 2019				instrance				
Gross written premium	574	1,843	461	2,315	816	-	267	6,276
Net earned premium	286	796	199	946	462	-	118	2,807
Gross claims incurred	(407)	(1,344)	(336)	(984)	(625)	(91)	(158)	(3,945)
Net claims incurred	(213)	(588)	(147)	(484)	(371)	(10)	(71)	(1,884)
Direct expenses incurred	(61)	(193)	(48)	(479)	(95)	-	(47)	(923
Year ended 31 December 2018								
Gross written premium	556	1,550	387	2,165	501	-	262	5,42
Net earned premium	284	764	191	927	230	-	121	2,517
Gross claims incurred	(404)	(886)	(267)	(1,005)	(283)	77	(148)	(2,916,
Net claims incurred	(212)	(413)	(144)	(481)	(131)	9	(71)	(1,443)
Direct expenses incurred	(58)	(166)	(41)	(481)	(78)	-	(54)	(878)

The material SII lines of business underwritten by the Company, in order of the value of gross written premium, as presented in QRT S.05.01 (Appendix F.1.2.1 and F.1.2.2), are:

	%	%
Year ended 31 December	2019	2018
Fire and other damage to property insurance	37	40
Motor vehicle liability insurance	30	29
General liability insurance	13	9
Medical expense insurance	9	10
Other motor insurance	7	7
Other SII lines of business	4	5
Total	100	100

¹ Consistent with the treatment adopted in the Group, the Company's underwriting profit for 2018 has been restated from £136m to £120m to include net amortisation costs of £16m, previously included within Performance of other activities.

In addition to the developments described in section A.2.2, comparison of QRT S.05.01 for the year ended 31 December 2019 with that for 2018 is affected by the following factor, which impacts QRT S.05.01 but is excluded from underwriting profit:

• Following the announcement of the Lord Chancellor on 15 July 2019 to increase the Ogden discount rate from the minus 0.75% set in 2017 to minus 0.25%, balance sheet reserves were calculated using a discount rate of minus 0.25% at 31 December 2019 (0.00% at 31 December 2018). This has resulted in a strengthening of claims reserves of £23m (net of reinsurance). The Ogden discount rate is expected to be reviewed by the Lord Chancellor within five years. Gross and net claims incurred for motor vehicle liability, other motor and general liability are particularly affected by the change in the Ogden discount rate.

A.3 Investment Performance

A.3.1 Measurement of investment performance

Net investment income, as shown in the Company's financial statements, is used as the measure to report the Company's investment performance.

Net investment income analysed by asset class

The table below provides an analysis of net investment income by asset class.

Net investment income £m	Investments in subsidiaries	Debt securities	Other financial investments	Loans with Group companies	Interest (payable) / receivable under quota share reinsurance with AIIL	Investment property	Total
Year ended 31 December 2019							
Dividend income	187		33				220
Interest income/(expense)		60	(6)	54	(127)		(19)
Unrealised gains/(losses)		33	145			3	181
Realised gains/(losses)		55	(140)				(85)
Rental income less expense						18	18
Other (incl. investment expenses)							(6)
Total	187	148	32	54	(127)	21	309
Year ended 31 December 2018							
Dividend income	107	-	30	-	-	-	137
Interest income/(expense)	-	77	(4)	58	30	-	161
Unrealised gains/(losses)	-	(108)	(92)	-	-	8	(192)
Realised gains/(losses)	-	68	(22)	-	-	-	46
Rental income less expense	-	-	-	-	-	15	15
Other (incl. investment expenses)							(2)
Total	107	37	(88)	58	30	23	165

The Company's net investment income for the year ended 31 December 2019 was £309m, which is £144m higher than the equivalent amount received in 2018 (£165m). The increase was driven by:

- A significant year on year swing in the total of realised and unrealised gains (gains of £96m in 2019 compared to losses of £146m in 2018), which were impacted by a fall in interest rates, tightening credit spreads and gains in equity markets in 2019; and
- An increase in dividends from subsidiaries (£187m in 2019 compared to £107m in 2018).
- This benefit was partly offset due to an increase in interest payable by the Company under the quota-share reinsurance arrangement with AIIL, (payment of £127m in 2019 compared to receipt of £30m in 2018).

Net investment income is stated after deduction of £6m (2018: £8m) of investment expenses.

A.3.2 Gains and losses recognised directly in equity

The material gains and losses recognised directly in equity during the year are summarised in the table below.

	£m	£m
Year ended 31 December	2019	2018
Foreign exchange rate movements	-	1

Further detail is provided in the Statement of Comprehensive Income in the Company's financial statements.

A.3.3 Investments in securitisation

The Company does not have any investments in securitisation.

A.4 Performance of Other Activities

A.4.1 Other income and expense

As described in section A.2.1, performance of other activities comprises those items of other income and expense, other than net investment return, excluded from underwriting result. The table in section A.2.2 summarises the loss of £119m (2018 restated: gain of £2m) that the Company sustained from its performance of other activities during the year. The material components are as follows:

Net contributions to closed defined benefit pension schemes: £29m (2018: £35m)

The Company has no employees. However, it is one of a number of companies in the Group being charged for the costs of staff participating in defined benefit pension schemes in the UK and its contributions are affected by the financial position of these schemes. The defined benefit sections for the schemes are now closed to both new members and future accrual. In the absence of any contractual arrangements to allocate the net defined benefit cost for these schemes, measured in accordance with IAS 19, to individual businesses it is the policy of the Group to allocate this cost fully to the main trading companies. The Company therefore recognises a pension expense equal to its contributions payable in the year. Full disclosure of the Group's pension schemes is given in the Annual Report and Accounts of the Group. The Company's net contributions to closed defined benefit pension schemes during the year were £29m (2018: £35m).

Impairment losses on the valuation of investments in subsidiaries £103m (2018: £46m)

Net impairments of £71m arose from the impairment of the cost of investment in two subsidiaries that paid dividends to the Company of £75m during 2019. A further £32m impairment arose against the Company's 31% holding in UKD, prior to the acquisition of additional shares in December 2019.

Increase in Ogden discount rate: expense of £23m (2018: income of £95m)

Following the announcement of the Lord Chancellor on 15 July 2019 to increase the Ogden discount rate from the minus 0.75% set in 2017 to minus 0.25%, balance sheet reserves were calculated using a discount rate of minus 0.25% at 31 December 2019 (0.00% at 31 December 2018). This has resulted in a strengthening of claims reserves of £23m (net of reinsurance). The Ogden discount rate is expected to be reviewed by the Lord Chancellor within five years. This has been included in other income and expense, a consistent treatment with the previous rate change.

Foreign exchange gains £45m (2018: losses of £12m)

Foreign exchange gains of £45m (2018: losses of £12m) have predominantly arisen on the Company's claims held in other currencies. The most material gain related to Euro denominated claims arising in Ireland.

A.4.2 Leasing arrangements

Net rental income from investment properties was £18m (2018: £15m).

The Company adopted IFRS 16 with effect from 1 January 2019. Under IFRS 16, lessees are required to recognise lease assets and liabilities on the statement of financial position for all leases, with the exception of short-term and low-value leases. Where the Company is the lessee, a lease liability equal to the present value of outstanding lease payments and a corresponding right-of-use asset equal to cost are initially recognised. The right-of-use asset is subsequently measured at amortised cost and depreciated on a straight-line basis over the length of the lease term. Depreciation on lease assets and interest on lease liabilities is recognised in the income statement.

Following the adoption of IFRS 16 the Company's interest expense in respect of lease liabilities was £2m (2018: operating lease costs: £21m). The treatment of the Company's right-of-use asset is described in section D.1.4 and the impact of adopting IFRS 16 is detailed in section D.1.10. Further information is provided in note 14 to the Company's financial statements.

A.5 Any Other Information

In February 2020 the directors declared interim dividends of £224m. Of these interim dividends, £182m was settled in cash and £42m was set-off against accrued interest due on the Company's loan to AGH.

In January 2020, ACI paid dividends of £23m (gross of withholding tax) in cash to the Company.

A.5.1 Additional information on the COVID-19 global pandemic

Further information on the impact of the COVID-19 global pandemic is contained within section F.5.

Aviva Insurance Limited

Solvency and Financial Condition Report 2019

B. System of Governance

In this Chapter

- B.1 General Information on the System of Governance
- B.2 Fit and Proper Policy
- B.3 Risk Management System including the Own Risk and Solvency Assessment
- B.4 Internal Control System
- B.5 Internal Audit Function
- B.6 Actuarial Function
- B.7 Outsourcing
- B.8 Any Other Information

B. System of Governance

This section of the report sets out information regarding the 'System of Governance' in place within the Company.

Details of the structure of the undertaking's 'administrative, management or supervisory body' (defined as including the Board, and Board committees) are provided. The roles, responsibilities and governance of key functions (defined as the Risk, Compliance, Internal Audit and Actuarial functions) are also provided. Other components of the system of governance are also outlined, including the risk management system and internal control system implemented across the business.


B.1 General Information on the System of Governance

B.1.1 Board structure

The Company's Board is responsible for promoting the long-term success of the Company and for setting its strategy. It sets the Company's risk appetite and satisfies itself that financial controls and risk management systems are robust. A strong system of governance throughout the Company aids effective decision-making and supports the achievement of the Company's objectives for the benefit of policyholders and the shareholder.

The Company's Board has established various committees and delegated responsibilities to assist in its oversight of risk management and the approach to internal controls. The duties of the Company's Board and of each of its committees are set out in their respective terms of reference. The terms of reference list both those items that are specifically reserved for decision by the Board and those matters that must be reported to the Board.

The diagram below shows the segregation of responsibilities between the various committees, in addition to a description of the main roles of each.



The Company's Board comprises the Chairman (an Independent Non-Executive Director (NED)), the CEO, the CFO, and six further NEDs (five independent and one nominated by the Group). The three committees comprise independent NEDs only.

The 'three lines of defence model', and roles and responsibilities of key functions

Roles and responsibilities for risk management in the Company are based around the three lines of defence model.

The first line

Management is responsible for the application of the Risk Management Framework, for implementing and monitoring the operation of the system of internal control and for providing assurance to the Audit, Conduct and Risk Committees and the Board.

The second line

- The Risk Management Function is accountable for the quantitative and qualitative oversight and challenge of the identification, measurement, management, monitoring and reporting of principal risks and for developing the Risk Management Framework;
- The Actuarial Function is accountable for actuarial methodology, and reporting to the relevant governing body on the adequacy of reserves and capital requirements, as well as on underwriting and reinsurance arrangements; and
- The Compliance Function supports and advises the business on the identification, measurement and management of its regulatory, financial crime and conduct risks and is accountable for monitoring and reporting on the Company's compliance risk profile.

The third line

The Internal Audit Function provides independent and objective assessment on the robustness of the Risk Management Framework and the appropriateness and effectiveness of internal control to the Audit, Conduct and Risk Committees, and to the Board.

Sections B.3.2, B.4.2, B.5 and B.6 detail the roles, responsibilities, authority, resources, independence and reporting lines of the Risk Management, Compliance, Internal Audit and Actuarial Functions respectively, and how their independence is ensured.

B.1.2 Material changes in the system of governance

During the year, Aviva adopted an organisational model whereby the General Insurance business is now managed separately from Aviva's other UK businesses. In line with this change, the Company has appointed a new CEO, CFO, CRO and CCCO. Notwithstanding this change, the Company's Board and Board Committee responsibilities and arrangements, and the fundamental approach to the system of governance, have not materially changed.

There have been no other material changes in the Company's systems of governance during the year.

B.1.3 Adequacy of the Company's system of governance

An assessment of the effectiveness of the Company's governance, internal control and risk management systems was conducted at the end of 2019, including a certification by the CEO. Key operational risks and any control weaknesses or non-compliance with the Company's risk policies and business standards or local delegations of authority are highlighted as part of this process. Substantial progress has been made during the year, especially in respect of IT and data related controls. The assessment identified further work to be undertaken around IT and data and to meet the Group's enhanced Financial Crime compliance standards, ongoing work in areas of regulatory focus and enhancements needed to implementation and embedding of the Risk Management Framework, including the Group's Operational Risk & Control Management methodology. The CRO provided his own opinion on the CEO's certificate which confirms accuracy of the CEO's declaration and noted no additional qualifications or weaknesses.

The Risk Committee, on behalf of the Board, carried out a full review of the effectiveness of the systems of internal control and risk management in March 2020 covering all material controls, including financial, operational and compliance controls and the Risk Management Framework. There has been regular reporting to the Audit Committee throughout the year to ensure that areas of improvement are both identified and remediated, and this monitoring will continue in 2020.

B.1.4 Remuneration policy

Aviva's reward principles and arrangements are designed to incentivise and reward employees for achieving stated business goals in a manner that is consistent with the Company's approach to sound and effective risk management. Aviva's remuneration policy is aligned to the Company's strategy, incentivises achievement of the Company's annual business plan and longer-term sustainable growth of the business, and differentiates reward outcomes based on performance and behaviour that is consistent with the Company's values.

Further details on the remuneration of Directors is included within note 6 – 'Directors' remuneration' of the Company's financial statements.

B.1.4.1 Executive directors

The remuneration policy provides market competitive remuneration and incentivises Executive Directors (EDs) to achieve both the annual business plan and the longer-term strategic objectives of the Company. Significant levels of deferral and an aggregate shareholding requirement align EDs' interests with those of shareholders and aid retention of key personnel. As well as rewarding the achievement of objectives, variable remuneration can be zero if performance thresholds are not met.

Remuneration of EDs is split between the following components:

- Basic salary informed by individual and business performance, levels of increase for the broader UK employee population and relevant pay data;
- Variable components (refer to section 'Variable components' below for further details);
- Pensions;
- Benefits;
- Relocation and mobility; and
- Shareholding requirement, in the shares of the ultimate parent company.

Variable components

The main forms of variable remuneration for EDs are:

- Annual bonus: Performance is assessed annually against a range of relevant financial, employee, customer and risk targets designed to incentivise the achievement of strategy as well as individual strategic objectives. A significant proportion of any bonus award is deferred into shares which vest in three equal tranches. Cash and deferred awards are subject to malus and clawback; and
- Long-Term Incentive Plan (LTIP): Shares are awarded which vest after a three-year period, in some cases dependent on the achievement of performance conditions over that period.

All variable pay elements are subject to Aviva's 'Malus and Clawback' policy.

Basic salaries are benchmarked externally, with fixed pay being set at a level which allows the variable component of pay to be fully flexible and proportionate, so that individuals do not rely on variable pay to meet the cost of living. Variable pay is subject to

individual, business unit and Group performance. Financial and non-financial criteria are used for assessing performance. Variable pay is fully flexible with the possibility of zero pay out in certain circumstances, including when employees have underperformed, taking into account business performance and risk, conduct and compliance factors.

B.1.4.2 NEDs

NEDs receive a basic annual fee in respect of their Board duties. Further fees are paid for membership and, where appropriate, chairing Board committees. The Chairman receives a fixed annual fee. Fees are reviewed annually taking into account market data and trends and the scope of specific Board duties.

The Chairman and NEDs do not participate in any incentive or performance plans or pension arrangements and do not receive an expense allowance.

NEDs are reimbursed for reasonable expenses, and any tax arising on those expenses is settled directly by the Company. On the limited occasions when it is appropriate for a NED's spouse or partner to attend a business event, the Company will meet these costs and any tax liabilities that may arise.

B.1.4.3 Other Employees

Remuneration arrangements for employees that are not EDs take account of the seniority and nature of the role, individual performance and local market practice. The components and levels of remuneration for different employees may therefore differ from the policy for EDs. Any such elements are reviewed against market practice and approved in line with internal guidelines and frameworks.

Variable payments are discretionary and fully flexible as opposed to a contractual entitlement, and there is a possibility of zero awards being made should the performance of the Company and/or individuals require this (other than where payments are required by law). Individual awards are based on an assessment of performance of individuals allowing for differentiation.

The remuneration of employees in Control Functions (defined as Risk, Compliance, Internal Audit and Actuarial Functions within Aviva) is determined independently of the financial results of the business areas they oversee. This reinforces the independence of these Functions.

Shares in the ultimate parent company can be awarded to employees under the LTIP. These vest after three years, in some cases dependent on performance conditions over that period.

B.1.4.4 Pension and early retirement schemes

The Company did not operate any enhanced pension arrangements or early retirement schemes during the reporting period.

B.1.5 Material transactions with the shareholder, persons with significant influence on the Company and members of the Board

No material transactions have been identified during the period with persons who exercise a significant influence on the undertaking, or with members of the administrative, management or supervisory body.

Key management personnel may from time to time purchase insurance, savings, asset management or annuity products marketed by Group companies on equivalent terms to all employees of the Group. In 2019 other transactions with key management personnel were not deemed to be significant either by size or in the context of their individual financial positions.

Additional information on the material transactions with the Company's shareholder is included within note 36 – 'Related party transactions' of the Company's financial statements.

B.2 Fit and Proper Policy

B.2.1 Requirements for the persons who run the Company or who are other key function holders

For persons responsible for running the undertaking or responsible for key functions an assessment of fitness and propriety must consider their allocated responsibilities and skills and experience across the following areas:

- Insurance and financial markets;
- Business strategy and business models;
- System of governance;
- Financial and actuarial analysis;
- Regulatory framework and requirements; and
- Skills relevant to that role.

The Company's requirements in respect of skills, knowledge and expertise for key function holders are set following engagement with both internal and external subject matter experts in each specialism. These requirements and qualifications are captured within individual role descriptions for each key function role.

B.2.2 Process assessing fitness and propriety

The Company has implemented processes to ensure that individuals employed within it, or acting on its behalf, are both fit and proper in line with the PRA and FCA Fit and Proper requirements for individuals subject to the Senior Managers and Certification Regime (SMCR). This means that, as part of recruitment and employee screening, an individual's career history will be assessed and validated to establish whether an individual's skills and knowledge are appropriately matched to the role. It also means that checks are in place to ensure that an individual is honest, of good reputation, has integrity and is financially sound.

The governance over the fitness and propriety of individuals includes recruitment, performance management and training. However, to ensure that the Company protects itself against employing individuals who potentially could threaten its customers, properties, facilities or reputation, the majority of its fitness and propriety processes take place at recruitment and more specifically at pre-employment screening. A minimum set of basic screening requirements has been agreed and implemented. Additional enhanced screening requirements are applied for individuals who are approved or certified under SMCR and the fitness and propriety of these individuals is assessed annually.

Individuals approved or certified under the SMCR regime are required to complete a detailed assessment annually to verify their compliance with fitness and propriety requirements. Approved individuals are required to provide a further half-yearly statement of ongoing compliance.

B.3 Risk Management System including the Own Risk and Solvency Assessment

B.3.1 Risk Management Framework

The Risk Management Framework forms an integral part of management and Board processes and the decision-making framework across the Company. The key elements are:

- Risk appetite;
- Risk governance, including risk policies and business standards, risk oversight committees and roles and responsibilities; and
- The IMMMR processes including the use of risk models and stress and scenario testing (SST).

For the purposes of risk identification and measurement, risks are usually grouped by risk type: credit, market, liquidity, general insurance, and operational risk including conduct risk. Risks falling within these types may affect a number of metrics, including those relating to balance sheet strength, liquidity and profit. They may also affect the performance of products delivered to customers and service provided to customers and distributors, which can be categorised as risks to brand and reputation or as conduct risk.

To promote a consistent and rigorous approach to risk management the Company has adopted a number of risk policies and business standards which set out the risk strategy, appetite, framework and minimum requirements for its operations. Compliance with these policies and standards is confirmed annually.

A regular top-down key risk identification and assessment process is carried out by the Risk Function. This includes the consideration of emerging risks and is supported by deeper thematic reviews. This, together with the risk and control self assessment ("RCSA") process, are the main processes used to IMMMR risks. The RCSA process is run by the first line, with challenge by the Risk Function. It focuses on operational risks, which are recorded on iCARE, the Company's risk management system. The risk assessment processes are run separately but are complementary. They are used to generate risk reports which are shared with the relevant risk committees.

Risk models are an important tool in the measurement of risks and are used to support the monitoring and reporting of the risk profile and in the consideration of the risk management actions available. A range of stress (where one risk factor, such as equity returns, is assumed to vary) and scenario (where combinations of risk factors are assumed to vary) tests are undertaken to evaluate their impact on the business and the management actions available to respond to the conditions envisaged.

The Risk Function is accountable for quantitative and qualitative oversight and challenge of the IMMMR process and for developing the Risk Management Framework. Internal Audit provides an independent assessment of the risk framework and internal control processes.

Board oversight of risk and risk management is maintained on a regular basis through the Risk Committee. The Board has overall responsibility for determining risk appetite, which is an expression of the risk the business is willing to take. Risk appetites are set relative to capital and liquidity.

Economic capital risk targets are also set for each risk type, calculated on the basis of the SII balance sheet. The Company's position against risk appetite is monitored and reported to the Board on a regular basis. Long-term sustainability depends upon the protection of franchise value and good customer relationships. As such, the Company has a risk preference that it will not accept risks that materially impair the reputation of the Company and requires that customers are always treated with integrity.

During most of 2019, the Asset & Liability Committee (ALCO) and Operational Risk & Conduct Committee (ORCC) operated as management committees at UK Insurance (UKI) level and were chaired by the UKI CFO and UKI Chief Operating Officer respectively. The ALCO assisted the CFO with the discharge of his responsibilities in relation to management of the Company's balance sheet within risk appetite and provided financial and insurance risk management oversight. The ORCC, a management committee chaired by the Chief Operating Officer, supported the first line owners in the discharge of their responsibilities in relation to operational and conduct risk management. Since the separation of UK businesses into distinct business units, the Company has established its own equivalent management committees with similar remits. Both committees are chaired by the Company CFO. These committees have been supplemented by other management committees focused solely on the Company throughout the year.

To further support the role of risk management in decision-making processes, the role of the 'first line' is critical as part of the three lines of defence model. The CEO is responsible for the implementation of the Company's strategies, plans and policies, the monitoring of operational and financial performance, the assessment and control of financial, business and operational risks and the maintenance and ongoing development of a robust control framework and environment in their areas of responsibility.

B.3.2 Risk Function

The Risk Function is responsible for the design and implementation of the Risk Management Framework, and the design, implementation and independent validation of the IM. The Risk Function reports to the Company's Board on material risks, together with any other specific areas of risk requested by the Board, and assists the Board and management in the effective operation of the Risk Management Framework including, amongst other things, the provision of specialist analysis and quality reviews, an aggregated view of the risk profile, and an assessment of the key risks associated with the business's strategy, major projects, strategic investments and other key decisions.

The Risk Function has authority to review all areas of the Company and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work. The CRO has direct management accountability for the Risk Function. Appointment and removal of the CRO are matters reserved for the Board, on the recommendation of the Risk Committee, which supports the independence of the Risk Function.

B.3.3 Own Risk and Solvency Assessment

The Company considers that its Own Risk and Solvency Assessment (ORSA) comprises all the processes and tools that underpin the consideration of risk and capital implications in key decisions, including business planning. It provides a continuous and forward-looking assessment of the short-term and long-term risks that the Company faces, or may face, and ensures that its capital requirements are met at all times. In this context, the Board has confirmed the use of the regulatory capital requirement plus a risk appetite buffer as the Company's own measure of capital for the purposes of the ORSA.

The ORSA comprises a number of elements of the Risk Management Framework, which are embedded in the business through the requirements of the business standards around capital allocation, strategy, business planning and stress testing. These elements create an overview of the impact of risk on the business, which are taken into account by management in day-to-day decision-making. In particular, using economic capital in decision-making ensures risk and capital management are connected. The outcomes of the ORSA processes provide the Company's Board and management with insights on the key risks and current and future capital requirements.

The CEO and his direct reports are responsible for the majority of the underlying ORSA processes set out above. The Risk Function is responsible for the design of the Risk Management Framework, including the ORSA Policy and annual ORSA reporting.

Review and approval

The outputs from the ORSA processes are reported to and reviewed by the Board and the Risk Committee regularly during the year. The Risk Committee sets the approach to the ORSA and, on behalf of the Board, oversees the ORSA processes including the identification of risk, the methodology and assumptions used in the IM, and the results of the IM validation exercise. The results of the Company's ORSA processes are considered by the Board when reviewing the Company's strategy and approving annually the business and capital plan.

The annual ORSA Report brings together and summarises a high-level description of the key components of ORSA, together with key developments and outcomes during the year. It provides a forward-looking assessment of the risk and solvency needs of the Company over a 3-year time horizon, reflecting the company's strategy and business plans. The ORSA processes and associated ORSA report play a key role in supporting decision making and strategy development at the Company's Board and Risk Committee.

Outputs of the underlying ORSA processes are presented to the Board and its committees throughout the year. The subsequent ORSA report is produced and approved by the Board annually, or in the event that ORSA triggers are met (per its ORSA policy). For example, an out of cycle ORSA update may be triggered (at the discretion of the Board), in the event of:

- An actual or projected material impact on the Company's Own Funds or diversified SCR compared to Plan;
- The invocation of the Crisis Action Leadership Team (under the Financial Event Response Plan);
- More broadly any potentially material change to the Company's risk profile.

The annual report is submitted to the Board, and subject to their approval shared with the PRA.

Economic capital (as a risk-based capital measure) is embedded in the Company's Risk Management Framework and is used as a key input to a wide range of business and strategic decisions. The framework, supported by risk policies and business standards, sets out the areas where economic capital management information must be used as part of decision-making and risk management processes. This ensures that requirements to use economic capital are embedded within the relevant processes including, but not limited to, strategy and planning. Economic capital is calculated using the IM or through the SF calculation, and aggregated to determine the Company's economic capital requirement using its PIM.

B.3.4 Governance of the IM

The CRO is the ultimate owner of the IM. The day-to-day responsibilities are delegated to the Chief Actuary. The Chief Actuary gives assurance to the Risk Committee that the IM is appropriate for use on an ongoing basis. He also confirms the IM adequately reflects the Company's risk profile, is accurate and works effectively.

The SII IM and Data Governance Business Standards are part of the overall Risk Management Framework. These combine to ensure that the Company operates within a controlled environment when developing methodologies and assumptions and when running processes and systems.

The Risk Committee is responsible for approving any material IM changes before submission to the College of Supervisors for approval. The quarterly model change reports, and supporting evidence, provide the required information to support Risk Committee and the College of Supervisors' approval.

There has been no material change to the governance of the IM during 2019.

Validation process

The Company's IM is validated by testing the individual calibrations and methodologies that are input into the model and the results that are output from the model. The validation tests applied comprise both mathematically defined tests and those based on qualitative judgement. Key tests include benchmarking, back-testing and sensitivity testing. The validation tests are run, documented and assessed against criteria which are designed to draw conclusions on the appropriateness of the IM.

The Internal Model Independent Validation (IMIV) Business Standard defines the scope of IMIV. The Risk Director reviews the findings of the exercise and provides an opinion to the Risk Committee as to whether the IM is suitably accurate and fit for purpose, and whether it is recommended for approval by the Board.

B.4 Internal Control System

B.4.1 System of Internal Control

The Company's principles for ensuring effective internal control are set out in the Risk Management Framework and, in particular, the Internal Control Business Standard. These include:

- An appropriate "tone from the top". This supports the effective management of exposures, adequate resourcing, effective communication, malpractice reporting, a business ethics code that is annually signed up to by employees, and a commitment to integrity, ethical behaviour and compliance;
- A clear organisational structure that supports the system of internal control and includes the effective operation of an
 adequately resourced three lines of defence model, appropriate and proportionate segregation of duties, a clear system
 of delegated authorities, clearly defined roles and responsibilities for staff, and the consideration of risk management and
 control responsibilities when setting objectives for, and reviewing the performance of, all staff;
- Implementation of risk policies and business standards, and consistent IMMMR of all risks;
- Effective controls for each of its core business processes which are regularly monitored and reported on; and
- A risk oversight process that provides adequate challenge to the completeness and openness of internal control and risk assessment.

B.4.2 Compliance Function

The primary purpose of the Compliance Function is to assess and manage exposure to regulatory risk. The Compliance Function is an integral part of the Risk Management Framework and constitutes a key part of the Company's corporate governance, including relationships with the FCA and the PRA, and other regulatory bodies. The function is a critical contributor to the safe and sound operation of the Company and underpins the achievement of its strategy and business goals. The key processes that comprise the Company's compliance activity are:

- Conduct regulatory risk management (including monitoring regulatory developments), performed by the Compliance Function and including activities such as:
 - Setting the conduct and financial crime policy framework;
 - Providing advice, support, guidance and challenge on conduct and financial crime risk; and
 - Managing conduct and financial crime regulatory engagement.
- Prudential regulatory risk management (including monitoring regulatory developments), performed by the Risk Function and including activities such as:
 - Setting the prudential regulatory risk policy framework;
 - Providing advice, support, guidance and challenge on prudential regulatory risk; and
 - Managing prudential regulatory engagement.
 - Legal developments monitoring, performed by the Legal & Company Secretarial Function.

Through these processes the Compliance, Risk and Legal Functions also take responsibility for reporting information to the Board and its committees. The oversight of conduct risk has remained a key focus of the Conduct Committee during 2019. From 2020 the Committee will receive a report from the CCCO at each meeting, and received a report from the CRO at each meeting in 2019, which covers any material concerns regarding conduct risk and the treatment of customers generally, along with details and an assessment of the adequacy of management's response.

The CRO has responsibility for prudential regulatory risk management and the CCCO has responsibility for conduct regulatory risk management (both responsibilities were held by the CRO during most of 2019), whilst the General Counsel is responsible for monitoring legal developments. Those carrying out compliance activities have authority to review all areas of the Company and have full, free and unrestricted access to all activities, records, property and personnel necessary to complete their work, where appropriate.

B.5 Internal Audit Function

The Company's Internal Audit Function is led by the Audit Director who reports directly to the Group Chief Audit Officer and to the Chairman of the Company's Audit Committee.

The Internal Audit Function provides regular reports to the Company's Audit Committee on the robustness of the Company's Risk Management Framework and the appropriateness and effectiveness of the system of internal control. In doing this it considers the adequacy of the Company's system of internal control to manage its business risk and to safeguard its assets and resources. It also considers the effectiveness of any actions put in place by management to address any deficiencies that might exist in the system of internal control.

The Internal Audit Function investigates and reports on cases of suspected financial crime and employee fraud and malpractice, and undertakes designated advisory projects for management.

Independence and objectivity

The Internal Audit Function maintains its independence and objectivity by reporting directly to the Group Chief Audit Officer and the Chairman of the Company's Audit Committee. The Audit Committee has a duty to recommend the appointment or dismissal of the Audit Director to the Board and to participate, jointly with the Chief Audit Officer or designee, in the determination of the objectives of the Internal Audit Director and the evaluation of his levels of achievement, including consultation with the CEO.

The Audit Director proposes a budget which ensures that Internal Audit has sufficient skills and resources to discharge its responsibilities. Internal Audit is authorised to review all areas of the Company and has full, free, and unrestricted access to all activities, records, property, and personnel necessary to complete their work.

Internal Audit Function staff have no direct responsibility for any operational activities. There is a formal policy of rotating staff to ensure that independence is maintained. There is also a restriction on the audits that staff who have previously worked elsewhere in the Company can perform. The Internal Audit Function cannot perform any projects for management that will threaten its actual or perceived independence and objectivity.

An annual declaration of independence is signed by all members of the Internal Audit Function's staff.

B.6 Actuarial Function

The Actuarial Function is accountable for actuarial methodologies and calibrations, plus the resultant Best Estimate Liabilities and capital requirements. It also considers the appropriateness of the IM, supports the IM validation exercises and maintains the IM change log. The Actuarial Function produces an annual report to the Board providing all of the information necessary for the Company's Board to form their own opinion on the adequacy of Technical Provisions and on the Company's underwriting and reinsurance arrangements.

The independence of the Actuarial Function is derived through its membership in the wider Risk Function. The Actuarial Function is led by the Chief Actuary, who reports to the Company's CRO. Persons employed in certain specific roles within the Actuarial Function are subject to the Fit and Proper policy requirements to ensure they have the requisite skills and knowledge to complete their responsibilities. (Fit and Proper requirements are considered in section B.2.).

The Actuarial Function has the authority to review all areas of the Company and has full, free and unrestricted access to all activities, records, property and personnel necessary to complete its work.

B.7 Outsourcing

Policy

The Procurement and Outsourcing Business Standard contains information on the Company's outsourcing policy, setting out the relevant responsibilities, objectives, process, and monitoring arrangements to be applied in cases of outsourcing, all of which shall be consistent with the overall strategy. The Business Standard applies equally to any externally or internally (intra-group) outsourced activity. The objective of this Business Standard is to ensure that minimum control objectives and controls for supplier-related activities are followed by all elements of the business, to ensure that supply risk is managed effectively, customers are being treated fairly and continue to receive good outcomes, as well as mitigating potential financial, operational, contractual, and brand damage caused by inadequate management.

The Business Standard aligns with UK regulatory expectations, the FCA, the PRA, SII and where appropriate, regulatory guidance will be applied as a requirement. The Business Standard applies to all staff involved in supplier-related activities and provides direction to staff on their roles and responsibilities in effectively managing supplier activity. It provides clarity on the definition of outsourcing, including where activity is delegated to an intermediary, and whether an outsourced function or activity is assessed as critical or important. All staff have a responsibility to comply with this Business Standard if they are involved with supplier-related activity.

The Board has approved the objectives and controls in the Business Standard which cover the following areas:

- Supply governance: business oversight of operational performance for sourcing and supply management activities;
- Sourcing: how a service provider of suitable quality is selected;
- Supplier contracting and approvals: financial, commercial and legal approval of contracts; and
- Supplier management and business continuity: risk-based approach to management of supply contracts including operational resilience.

Critical or important outsourcing will attract the highest level of rigour, including regulatory notification, performance and relationship reviews, regulatory compliance reviews, and risk and control assessments.

Critical and important outsourced functions and activities

The Company outsources a range of activities consistent with its outsourcing strategy. These include elements of underwriting, customer contact, including claims handling, IT, accounting services, property services and investment management. Critical or important outsourced operational activities include handling of mobile device and travel insurance claims and provision of data centres.

Jurisdiction of service providers

Critical or important outsourced activities are carried out mostly in the UK, but also in several other jurisdictions. The latter includes international claims predominantly in the location of the insured risk and support functions in India and Sri Lanka. Investment management services are outsourced within the Group in the UK.

B.8 Any Other Information

B.8.1 Additional information on the COVID-19 global pandemic

Further information on the impact of the COVID-19 global pandemic is contained within section F.5.

Aviva Insurance Limited

Solvency and Financial Condition Report 2019

C. Risk Profile

In this Chapter

- C.1 Underwriting Risk
- C.2 Market Risk
- C.3 Credit Risk
- C.4 Liquidity Risk
- C.5 Operational Risk
- C.6 Other Material Risks
- C.7 Any Other Information

C. Risk Profile

The 'Risk Profile' section of this report provides information on the key risks encountered by the Company as well as the corresponding processes for monitoring the risk exposures and the techniques in place for mitigating these risks. Comments have been included in the following sections to highlight where the Company is exposed to underlying risk arising from subsidiary businesses including ACI and AIIDAC.

C.1 Underwriting Risk

C.1.1 Exposure

The Company's exposure to non-life (including health similar to non-life) insurance underwriting risk in the UK, Ireland and Canada arises from:

- Inadequate claims reserving assumptions;
- Unforeseen fluctuations in the timing, frequency and severity of claims and claim settlements relative to expectations;
- Unexpected claims arising from a single source;
- Inaccurate pricing of risks or inappropriate underwriting of risks when underwritten; and
- Inadequate reinsurance protection or other risk transfer techniques.

The Company does not underwrite life insurance business, or health products similar to life insurance. Longevity risk, associated with bodily injury claims settled as PPOs, is reinsured with Aviva Life & Pensions UK Limited (UKLAP), a fellow Group company.

The Company has a preference for general insurance risk in measured amounts for explicit reward, in line with its core skills in underwriting and pricing. This includes the following risks ceded to the Company:

- Under an inwards reinsurance agreement with its subsidiary undertaking, Gresham Insurance Company Ltd (Gresham), with effect from 1 January 2006 whereby nearly all of Gresham's premiums, claims and expenses are reinsured by the Company.
- Under an inwards adverse reserve deterioration agreement with its subsidiary undertaking, The Ocean Marine Insurance Company Ltd (Ocean Marine) (see section C.3.2).
- On 1 February 2019, as part of its Brexit strategy, the Company transferred a subset of its insurance business to its Irish domiciled subsidiary (AIIDAC). A quota share agreement with AIIDAC transfers the majority of these risks back to the Company, through a quota share reinsurance agreement which broadly covers 85% of the Ireland branch risks and 100% of other risks. Further details are provided in section A.1.2.

The Company has the following outwards reinsurance arrangements in place:

- A 50% internal quota share reinsurance agreement with AIIL, further details on this agreement are provided in section A.2.2 and section C.3.2.
- From 1 January 2019 ACI has entered into a 25% internal quota share reinsurance agreement with AIIL.

Outside of the reinsurance changes detailed above, the Company's underlying exposure to underwriting risk has remained relatively stable. Following the announcement of the Lord Chancellor on 15 July 2019 to increase the Ogden discount rate from the minus 0.75% set in 2017 to minus 0.25%, balance sheet reserves were calculated using a discount rate of minus 0.25% at 31 December 2019 (0.00% at 31 December 2018). This has resulted in a strengthening of claims reserves of £23m (net of reinsurance). The Ogden discount rate is expected to be reviewed by the Lord Chancellor within five years. The July 2019 announcement is considered to reduce uncertainty within the shorter term, however uncertainty does remain in the medium to longer term as the Lord Chancellor will review the Ogden discount rate at least every five years and has also asked for further review on the advantages and disadvantages of a dual rate regime. Any change in the Ogden rate would impact underwriting risk exposure because it affects the amount of awards for lump sum bodily injury claims and therefore also the tendency for claimants to settle on a lump sum basis rather than as a PPO.

The Company's overall exposure to underwriting risk is measured using the SCR. QRT S.25.02.21 (Appendix F.1.7) shows that the Company's undiversified SCR for underwriting risk is £686m (2018: £838m). This reduction includes the impact of the AIIL-ACI reinsurance agreement entered into in 2019 (as noted above). Underwriting risk is also measured and monitored in terms of best estimate liabilities, total sum insured and estimated maximum loss. Estimated maximum loss is an estimation of the maximum loss that could be reasonably sustained as a result of a single incident considered to be within the realms of probability. There has been no material change to the measures used to assess underwriting risk during the reporting period.

C.1.2 Risk concentration

The Company avoids underwriting risk concentration through its scale, geographical distribution of underwriting risks, diversity of product lines and diversity of distribution channels. Individual risks and groups of risk are only accepted if, after diversification and reinsurance, the residual risk is within appetite. Controls are in place to ensure accumulations of risk are identified, evaluated and controlled.

The Company's general insurance risk is located in the UK and Ireland. The Company is also exposed to the underlying general insurance risk arising from subsidiary businesses; including ACI, which operates in Canada and AIIDAC, which operates in Ireland. This is managed locally but is captured within the Company's SCR. The Company's most concentrated non-life underwriting perils are North European Windstorm and British Columbian Earthquake.

C.1.3 Risk mitigation

The Company manages its exposure to general insurance risk through the application of control frameworks that include:

- Claims reserving that is undertaken by actuaries and is also subject to periodic internal and external review;
- Risk appetites to limit exposures to key general insurance risks;
- Extensive use of data, financial models and analysis to improve pricing and risk selection;
- Underwriting limits linked to delegations of authority that govern underwriting decisions;
- Product development in a management framework that ensures products and propositions meet customer needs;
- Product limits and exclusions;
- Governance of outsourced functions writing products on behalf of the Company; and
- Documented claims management philosophies and procedures.

The primary technique used to mitigate underwriting risk is reinsurance. Reinsurance is purchased to mitigate underwriting risk and to maintain exposures within appetite. In some cases, the Company participates in Group reinsurance programmes, which leverage economies of scale whilst allowing the Company to trade to the full extent of its underwriting appetite.

The Company and its subsidiaries have a number of reinsurance agreements in place, with both internal and external counterparties, to mitigate underwriting risk. Major reinsurance agreements include:

- Catastrophe reinsurance providing protection against the risk of natural hazard events (e.g. earthquake, windstorm);
- Reinsurance of most of the Company's legacy UK latent claims reserves;
- Reinsurance of the legacy London Market claims reserves of the Company's subsidiary undertaking, Ocean Marine;
- Reinsurance of longevity risk on the Company's bodily injury claims settled as PPOs;
- The 50% quota share reinsurance agreement between the Company and the Group's internal reinsurance vehicle, AllL and the 25% quota share reinsurance agreement between ACI and AllL. Further details are provided in section C.3.2;
- Reinsurance of specific flood risks to Flood Re Limited;
- Reinsurance of terrorism risk to Pool Reinsurance Company Limited;
- Casualty excess of loss reinsurance providing protection against the risk of large losses arising from motor liability or general liability insurance; and
- Property excess of loss reinsurance providing protection against the risk of large losses arising from property insurance.

Reinsurance purchases are reviewed to verify that the levels of protection being bought reflect any developments in exposure and the risk appetite of the Company. The basis of these purchases is underpinned by extensive financial and capital modelling and actuarial analyses which consider the cost and capital efficiency benefits. This may involve utilising externally sourced probabilistic models to verify the accumulations and loss probabilities based on specific portfolios of business. In addition to external models, scenarios are developed and tested using Company data to determine potential losses and appropriate levels of reinsurance protection. Reinsurance covers single large exposures and concentrations of exposures.

The management of insurance risk is overseen by specific senior management committees, namely the Insurance Committee, the Reserve and Projections Committee and the ALCO.

C.1.4 Stress and scenario testing and sensitivity analysis

Descriptions of the methods used, assumptions made and outcomes of stress and scenario testing and sensitivity analysis are provided in section C.7.1.

C.1.5 Special purpose vehicles

The Company has not transferred underwriting risk to special purpose vehicles, as defined by the SII Directive.

C.2 Market Risk

C.2.1 Exposure

The Company's exposure to market risk arises from the risk of adverse financial impacts resulting directly or indirectly from fluctuations in interest rates, equity prices, property prices, foreign currency exchange rates and inflation. Market risk arises due to fluctuations in both the value of liabilities and the value of assets held. In addition to its own risks, the Company's SCR also includes the underlying risks of its subsidiaries, including its principal subsidiaries ACI and AIIDAC.

Interest rate risk arises primarily from the Company's fixed income securities and liabilities, which are exposed to fluctuations in interest rates. The Company seeks to match assets to liabilities and uses interest rate derivatives to meet its interest rate risk appetite.

Property price risk arises from the Company's investments in investment property and property investment vehicles. Property price risk is accepted by the Company to drive investment return as part of the Company's investment strategy.

Equity risk arises from the level or volatility of market prices for equities. Equity risk is accepted by the Company to drive investment returns as part of the Company's investment strategy, including the use of equity derivatives to mitigate risk where considered appropriate. The Company is also exposed to global market risks through its holdings in a unitised target return fund (Aviva Investors Multi Strategy Fund).

The Company is exposed to inflation risk where there is a mismatch between assets and liabilities that are sensitive to inflation. RPI elements of inflation risk are monitored and managed through asset-liability matching and hedging, where appropriate, in accordance with the agreed risk appetite.

The Company's material exposure to foreign currency risk arises primarily from: its investments in ACI and AIIDAC; the quota share agreement with AIIDAC ; the growth of GCS business lines; and non-domestic currency denominated investments. The Company seeks to match non-sterling liabilities from its Ireland exposure and international GCS business using a combination of non-sterling assets and currency derivatives to ensure liabilities in non-domestic currency can be settled as they fall due. The Company also seeks to mitigate the impact of foreign currency risk to its SII cover ratio (denominated in sterling) by using currency derivatives to hedge the contribution of ACI (denominated in Canadian Dollars). The Company also seeks to mitigate foreign currency risk on non-domestic denominated investments, where not matched to liabilities, by the use of currency derivatives.

The Company's overall market risk exposure has remained relatively stable during the reporting period.

The Company's overall exposure to market risk is measured using the SCR. QRT S.25.02.21 (Appendix F.1.7) shows that the Company's undiversified SCR for market risk is £768m (2018: £784m). This includes credit risk in respect of the Company's bond holdings whose risk profile and management is described in section C.3. In addition to the SCR, a number of risk-specific metrics are used to monitor market risk at a granular level:

- Key interest rate, Retail Price Index (RPI), and currency related parameters; and
- Changes in the price level of individual assets or specific asset classes, for example property prices.

There has been no material change to the measures used to assess market risk during the reporting period.

C.2.2 Risk concentration

The Company monitors its investment exposures in aggregate across all classes of financial instruments (debt securities, equities, derivatives and other investments), to individual issuers, geographies, sectors, and asset classes.

The Company's largest foreign currency exposure is to the Canadian Dollar, via ACI, with currency forward derivatives in place to hedge the foreign exchange risk to the Company's SII cover ratio position. The valuation of assets and liabilities are materially impacted by movements in market-implied interest rates and inflation, with those risks being managed within pre-defined risk appetites using a combination of asset-liability matching and derivatives.

C.2.3 Risk mitigation

The Company manages market risk within its market risk framework, within local regulatory constraints and in line with established Group policy, including minimum principles for matching liabilities with appropriate assets. As described in section C.2.1, the Company monitors exposures to market risks and uses derivatives to mitigate interest rate, inflation, foreign currency exchange rate and equity risks.

The Company only uses derivatives to reduce risks and facilitate efficient portfolio management. Risks arising from use of derivatives for hedging purposes include basis risk, which is the risk of an unexpected adverse financial impact arising because the exposure covered by a risk-mitigation technique, such as hedging using derivatives, does not correspond to the Company's risk exposure. The Company controls derivative basis risk by applying strict controls to its processes for their administration and valuation. The Company's control framework for derivative risk is consistent with market and industry practice.

In accordance with the requirements of its Financial Risk Mitigation Business Standard, the Company assesses and documents the effectiveness of arrangements to mitigate market risk. This assessment is initially undertaken prior to deciding whether or not to enter into an arrangement, and considers the impact of the proposed arrangement on key metrics including:

- Risk measures, including economic capital; and
- Financial measures, including cash flow, IFRS operating profit, liquidity and expenses.

If the initial assessment indicates that the impact on key metrics is material, further assessments are carried out at regular intervals throughout the duration of the arrangement. These assessments typically include stress testing and sensitivity analysis. Transactions to mitigate the same risk may be considered in aggregate (e.g. programmes to mitigate interest rate risk or foreign exchange risk).

The Company conducts on-going monitoring of the effectiveness of market risk mitigation techniques by reporting management information and analysis to the ALCO and the Board's Risk Committee. Investment performance analysis including actual returns against expected are also reported to the ALCO and Board. Processes are also in place to monitor key economic data against predefined trigger points to enable appropriate oversight and actions to take place if economic conditions deteriorate, as set out in the Company's event response plans.

C.2.4 Stress and scenario testing and sensitivity analysis

Descriptions of the methods used, assumptions made and outcomes of stress and scenario testing and sensitivity analysis are provided in section C.7.1.

C.3 Credit Risk

C.3.1 Exposure

The Company's exposure to credit risk arises from the risk that it will incur a financial loss from the default or failure of third parties to meet their payment obligations to the Company, or variations in market values as a result of changes in expectations related to these risks. In addition to its own risks, the Company's SCR also includes the underlying risks within its subsidiaries, including its principal subsidiaries ACI and AIIDAC.

The Company's approach to managing credit risk recognises that there is a risk of adverse financial impact resulting from fluctuations in credit quality of third parties including default, rating transition and credit spread movements. The Company's credit risks arise principally from exposures to debt securities, insurance debtors, reinsurance counterparties and other assets such as bank deposits and derivative and securities financing counterparties.

The Company's management of credit risk includes implementation of credit risk management processes (including limits frameworks), and detailed reporting and monitoring of exposures against pre-established risk criteria. The management of credit risk is overseen by the ALCO.

The principal basis used to measure the Company's exposure to counterparty risk is the SCR. QRT S.25.02.21 (Appendix F.1.7) shows that the Company's undiversified SCR for counterparty risk is £101m (2018: £103m). Counterparty risk relates to the risk associated with reinsurers and insurance debtors. The Company is additionally exposed to the credit risk associated with investment bond holdings included in the market risk SCR reported in the QRT as described in section C2.1. The following metrics are also used by the Company when measuring and assessing its credit risk exposure and to support risk management actions and investment decisions:

- Maximum exposure: credit exposure of the Company's financial assets to counterparties;
- External credit rating: available Moody, Standard & Poor and Fitch ratings;
- Market adjusted credit ratings: external credit ratings modified for the market price of the counterparty's credit default swap; and
- Internal credit ratings: determined for broker counterparties that are not externally rated, using methodologies broadly consistent with those used by external rating agencies.

There has been no material change to the measures used to assess credit risk during the reporting period and the Company's exposure to credit risk, including counterparty risk, has remained relatively stable throughout the year.

The overall credit quality of the Company's financial investments is strong. At 31 December 2019, investment grade debt securities (external credit rating AAA to BBB) comprised 100% (2018: 100%) of total debt securities, with 70% of rating AA or above (2018: 69%). Reinsurance assets with external credit ratings of AA to A comprised 98% (2018: 97%) of total reinsurance assets.

C.3.2 Risk concentration

The Company's credit limit framework restricts investment in individual issuers, geographies, sectors, and asset classes to ensure the Company is not exposed to significant concentrations of credit risk.

The Company's main concentration of external credit risk arises from holding UK government debt securities. At 31 December 2019 the Company held £752m (2018: £1,024m) of UK government debt. The Company's biggest industry sector exposure is to worldwide bank debt securities (£385m (2018: £375m)). The majority (94% (2018: 96%)) of the Company's holding of bank debt securities are covered bonds or senior debt rated A or above.

Reinsurance

The Company's largest external reinsurance counterparty is Swiss Reinsurance Company Limited (including its affiliated companies). At 31 December 2019, the reinsurance asset recoverable is £794m (2018: £719m). This exposure is reduced by collateral comprising a portfolio of highly rated assets amounting to £206m (2018: £206m).

The Company's largest intra-group reinsurance counterparty is AIIL. At 31 December 2019, the reinsurance asset recoverable from AIIL (excluding unearned premium reserve) is £2,109m (2018: £2,181m). Credit risk is mitigated by a funds withheld arrangement, whereby the Company holds a balance equal to the higher of IFRS or SII technical provisions of the reinsured business.

The Company has an inwards adverse reserve deterioration agreement with its subsidiary undertaking, Ocean Marine. This agreement provides Ocean Marine with an extra £1bn of reinsurance cover to protect against circumstances in which its reinsurance agreement with National Indemnity Company (NIC) is exhausted or otherwise fails to satisfy claims. Ocean Marine's reinsurance agreement with NIC provides substantial protection in excess of its current gross insurance liabilities. As at 31 December 2019, Ocean Marine's exposure to NIC was £363m (2018: £381m).

The Company has an agreement with UKLAP, a fellow Group company, for the outwards reinsurance of its obligations in respect of PPOs. At 31 December 2019, the reinsurance asset recoverable from UKLAP is £568m (2018: £490m). The credit risk exposure is mitigated by a funds withheld arrangement. The Company retains legal title of the assets backing the reinsured liabilities whilst UKLAP retains beneficial ownership. The funds withheld are maintained quarterly to match the reinsurance asset

Loans

The Company has a loan facility agreement with AGH, the Company's immediate parent. During the year, the loan balance has been reduced by £51m to £1,268m at 31 December 2019 (2018: £1,319m). This reduction reflects the 2019 annual loan repayment of £50m and the transfer from AGH of the shares in Neos Ventures Limited, a new subsidiary of the Company. The loan continues to be secured on a range of Group undertakings. The loan has a final maturity date of December 2042.

The Company has a subordinated unsecured loan agreement with ACI. The loan, with a carrying balance of £204m (2018: £201m), has a final maturity date of March 2045. In the event that ACI's minimum regulatory capital requirement falls below certain local trigger levels, ACI may redeem the loan in exchange for issuing equity whose aggregate value is equal to the principal amount outstanding on the loan.

The Company also has a subordinated unsecured loan from AGH of £279m (2018: £276m). The Company used these proceeds to provide a subordinated unsecured loan to ACI of the same amount; both of these agreements have a final maturity date of June 2046.

Stock lending

The Company has entered into stock lending arrangements during the year in accordance with established market conventions, with the carrying amount of financial assets pledged for stock lending at 31 December 2019 of £380m (2018: £768m). The credit risk associated with the Company's securities financing operations is mitigated by over-collateralisation. The carrying amount of financial assets collateral received in this manner at 31 December 2019 was £410m (2018: £821m).

C.3.3 Risk mitigation

Risk mitigation techniques are used where and when deemed appropriate. These are utilised, where possible, to remove residual unwanted risks, as well as to bring or keep exposure limits within appetite, and include methods such as collateralisation and funds withheld arrangements.

As described in section C3.1 and C.3.2, the Company has in place a credit control framework to manage credit risk, and uses techniques including collateralisation and funds withheld arrangements to mitigate unwanted credit risk.

In accordance with the requirements of the Group Financial Risk Mitigation Business Standard the Company assesses and documents the effectiveness of arrangements to mitigate credit risk. On-going monitoring is carried out by reporting management information to the ALCO and the Board's Risk Committee, against pre-defined trigger points, to enable appropriate oversight and to prompt action if effectiveness deteriorates, as set out in the Company's event response plans.

C.3.4 Stress and scenario testing and sensitivity analysis

Descriptions of the methods used, assumptions made and outcomes of stress and scenario testing and sensitivity analysis are provided in section C.7.1.

C.4 Liquidity Risk

C.4.1 Exposure

The Company's exposure to liquidity risk arises from the risk that its liabilities cannot be settled, in a timely and cost-effective manner, as they fall due because of insufficient liquid assets. Liquidity risk may arise from uncertainty of the value and timing of liabilities or the ability to realise assets to produce cash to meet obligations. The Company assesses liquidity risk under a range of scenarios and various levels of liquidity stress. Sources of liquidity risk include:

- Insurance underwriting e.g. catastrophe claims arising from adverse weather events;
- Failure to receive payment from customers;
- Variances of actual operational cash flow from shorter-term forecasts; and
- Other cash flow volatility e.g. derivative and collateral calls arising from the Company's risk mitigation activities.

The principal bases used to measure and assess the Company's exposure to liquidity risk are liquidity coverage ratios, absolute liquidity coverage relative to pre-defined liquidity risk appetites and the quantum of certain liquid assets. Liquidity coverage ratios measure the extent to which available liquidity is sufficient to meet expected liquidity requirements following an extreme liquidity-specific stress event over short-term and long-term stress scenarios. Liquidity is also monitored in the event of a stressed run-off of the Company's liabilities following closure to new business and is managed within the Company's Stressed Run-Off Liquidity (STROL) risk appetite.

There has been no material change to the measures used to assess liquidity risk during the reporting period.

The Company's liquidity profile was maintained within appetite on both absolute and stressed liquidity coverage ratio bases, over going concern short-term and long-term scenarios, and under stressed run-off basis throughout the year, and overall there was no material movement in the Company's liquidity position against its risk appetite.

C.4.2 Risk concentration

The credit limit framework described in section C.3.2 above also avoids concentrations of liquidity risk by preventing investment in a restricted number of issuers, asset classes and sectors. The diversity of sources of liquidity available to the Company averts concentration of liquidity risk.

C.4.3 Risk mitigation

The Company manages its liquidity risk by considering the liquidity impact before accepting new risks and managing its existing liquidity profile by:

- Daily monitoring of projected short-term cash flow needs;
- Setting an investment strategy which reflects liquidity requirements and the potential liquidity profile of liabilities;
- Setting liquidity risk appetites which require that sufficient liquid resources be maintained to cover net outflows in a stress scenario over a range of timeframes;
- Defining trigger levels that enable action to be taken before those levels are breached; and
- Maintaining a Capital and Liquidity Management Action Plan (CLMAP) which details management actions to address liquidity funding requirements in a significant stress scenario.

The Company monitors the effectiveness of liquidity risk mitigation techniques as follows:

- The internal controls, that enable effective liquidity risk management, are subject to assurance testing to ensure they operate effectively; and
- Actual and projected liquid resources, cash inflows and outflows, as well as maturity analyses on insurance liabilities and financial assets, in both normal and stressed scenarios, are regularly reported to and monitored by the ALCO and the Board's Risk Committee, against pre-defined trigger points to enable appropriate oversight and identify any appropriate actions.

C.4.4 Expected Profit Included in Future Premium (EPIFP)

The amount of EPIFP, calculated in accordance with Article 1 of the SII Regulations and included within the valuation of the Company's Technical Provisions as at 31 December 2019, is immaterial. (See the Own Funds QRT S.23.01.01, Appendix F.1.6).

C.4.5 Stress and scenario testing and sensitivity analysis

Descriptions of the methods used, assumptions made and outcomes of stress and scenario testing and sensitivity analysis are provided in section C.7.1.

C.5. Operational Risk

C.5.1 Exposure

The Company's exposure to operational risk arises in the UK, and through its principal subsidiaries in Ireland and Canada, from the risk of direct or indirect loss, caused by inadequate or failed internal processes, people and systems, or external events including changes in the regulatory environment. The Company has a limited appetite for operational risk and aims to reduce these risks as far as commercially sensible.

Conduct risk, an element of operational risk, is where the Company does not achieve positive or fair customer outcomes. Management of conduct risk continues to be a key priority for the Company across the whole lifecycle of its products, and throughout the end to end journey of its customers, with robust governance and metrics embedded across the organisation.

The Company also seeks to manage its exposure to reputational risk, which is the risk of loss to the Company's franchise value from damage caused to the Company's brands or reputation. Examples of factors, regardless of whether authenticated or not, which could damage the Company's brands or reputation include litigation, employee misconduct, operational failures, the outcome of regulatory investigations, media speculation and negative publicity, disclosure of confidential client information or inadequate services.

The Company's strategy of digital customer interaction, its use of advanced data analytics and the increasing cyber security threat, together with regulators' attention to conduct issues, has increased its inherent exposure to risks such as data theft, conduct breaches and customer service interruption arising from IT systems failure, and these risks are expected to continue to increase into the future. However, the Company has sought to contain and reduce exposure to these risks through on-going investment in programmes to improve IT security and resilience, disaster recovery, data governance and outsourcing. The Company has an Operational Risk and Control Management Framework, which integrates the results of the risk identification and assurance activities carried out across the Company's three lines of defence.

Operational risks are initially identified through the Common Operational Risk Register (CORR) and assessed against implemented controls. Residual risk, outside tolerance, is given prioritised management action to reduce it within tolerance. Operational risk is quantitatively assessed on the basis of financial loss and misstatement. Potential reputational and conduct impacts are qualitatively assessed. There has been no material change to the measures used to assess operational risk during the reporting period.

The Company holds economic capital, based on the SII SCR, against residual operational risk, to the extent that it cannot be eliminated by management action. QRT S.25.02.21 (Appendix F.1.7) shows that the Company's undiversified SCR for operational risk is £358m (2018: £370m). The Company also produces specific conduct risk management information used to measure and analyse its exposure to conduct risk.

C.5.2 Risk concentration

The Company's scale and business model as a multi-business line, multi-locational and multi-channel business, creates diversification of risks and generally helps to reduce concentrations of risks particularly when risks across the Company and its subsidiaries are aggregated. The Company also works with a wide range of outsourcers to support delivery of its services and products. Further information is provided in section B.7.

The Company's operations are spread across a number of office locations that are geographically well spread, which would help ensure continuity of service in the event of catastrophe.

The majority of the Company's products are sold under the 'Aviva' brand, enabling leverage on the strength of the brand and supporting delivery of the Company's business strategy. The Company is therefore vulnerable to any operational failures that adversely impact public perception of the 'Aviva' brand.

C.5.3 Risk mitigation

Operational risks are considered by the Company to be preventable and are managed through business controls. The Company's operational risk strategy is to improve its business processes to:

- Reduce operational risk and associated losses, thereby improving cost to income ratio and variability in financial performance;
- Improve customer outcomes and employee satisfaction; and
- Sustain customer confidence and a positive regulatory reputation.

The Company's business standards set out the minimum control objectives and controls that each business area is required to operate. Operational risk tolerances are quantitative boundaries that constrain specific risk-taking activities at an operational level.

The Company records and analyses operational risk events to ensure remedial action is taken, lessons are learnt and, if the event impacts customers, they are treated fairly. This includes risk events that do not give rise to a financial loss, such as near misses or fortuitous gains. This assessment enables the Company to highlight areas for improvement, implement corrective actions to avoid recurrence, and improve its understanding of operational risk.

The Company has identified business critical functions and has exit and termination plans and business continuity and disaster recovery plans in the event of supplier failure. These plans are reviewed at least annually.

The Company's three lines of defence all monitor the effectiveness of the controls that are in place against operational risk. Further details of the three lines of defence are included in section B.1.1, including the specific roles and responsibilities of each line. Operational risk is overseen by the Operational Risk Committee, which is a senior management committee, and the Board's Risk, Conduct and Audit Committees.

C.5.4 Stress and scenario testing and sensitivity analysis

Descriptions of the methods used, assumptions made and outcomes of stress and scenario testing and sensitivity analysis are provided in section C.7.1.

C.6 Other Material Risks

The Company has no material information to disclose regarding other material risks.

C.7 Any Other Information

C.7.1 Stress and scenario testing and sensitivity analysis

SST is a fundamental element of the Company's Risk Management Framework which is embedded within the Company's decisionmaking, strategy and planning activities. SST provides insight into key risk exposures and dependencies of the Company; considering resilience of potential changes to these exposures and dependencies; and anticipating a range of possible outcomes. The evaluation of the potential impacts on the Company's capital and liquidity positions enables the Company to identify and prepare for appropriate ways to mitigate and manage the realisation of such impacts.

There are three main components of SST: (1) sensitivity analyses which consider single factor standalone impacts at a point in time to changes in economic and non-economic assumptions; (2) scenario analyses which consider impacts from specific potential events; and (3) the identification of plausible management actions.

The Company's stress and scenario methodology is based on the following stages:

- Identify existing and emerging risks;
- Measure resilience to stress events and scenarios;
- Monitor the impact of the potential stress events and scenarios on actual and projected capital and liquidity positions;
- Manage the potential stress events and scenarios by setting risk appetites and defining management actions; and
- Report, as required, to the ALCO, the Board's Risk Committee, the Board and the PRA.

C.7.1.1 Stress and scenario testing

At least annually, a broad range of Company risk specific stress and scenario tests are defined in consultation with key stakeholders to assess the impact of a range of potential events of differing levels of severity on the capital and liquidity positions of the Company. The stress and scenario tests performed by the Company, during 2019, included adverse economic conditions, catastrophic events, reserve deterioration, counterparty default, operational failings and Regulator defined tests.

A range of assumptions are made in the development of potential events and the measurement of resilience to such events. These assumptions are defined by suitable experts and, where applicable, by the Regulators.

The outcome of the Company's 2019 SST serves to illustrate that the Company is resilient to a wide range of potential events and that the Company has a range of plausible management actions that could be executed in a timely manner, to mitigate the potential impacts from Company-specific or market-wide events.

C.7.1.2 Sensitivity analysis

Management use sensitivity analyses to assess a range of single factor standalone impacts of differing levels of severity on the capital and liquidity positions of the Company and to ensure that the Company has a sufficient range of plausible management actions that could be executed in a timely manner to mitigate the potential impacts.

The sensitivity analysis performed by the Company includes consideration of the sensitivity of its SII cover ratio, determined according to the SII Regulations, to a range of assumption changes, including the impact on its underlying exposure to ACI and AIIDAC. The table below shows the absolute change in SII cover ratio, for each sensitivity, e.g. a 3% positive impact would result in an increase in the cover ratio by 3%.

Sensitivity to assumptions as at 31 December 2019	Impact on cover ratio
Economic assumptions	
25bps increase in interest rates	4%
50bps increase in interest rates	8%
25bps decrease in interest rates	-5%
50bps decrease in interest rates	-11%
50bps increase in corporate bond spreads	0%
50bps decrease in corporate bond spreads	0%
50bps increase in sovereign bond spreads	-6%
50bps decrease in sovereign bond spreads	6%
20% decrease in property values	-6%
25% decrease in equity prices	-4%
Non-economic assumptions	
5% increase in gross loss ratios	-16%

Limitations of the sensitivity analyses

The table above demonstrates the effect of a change in a key assumption while other assumptions remain unchanged whereas in reality, sensitivities are dynamic in nature as they will vary in quantum due to interactions with other risks and changes in values of those risks.

Other limitations in the sensitivity analyses include:

- The economic assumptions are hypothetical market movements selected to represent the Company's view of possible near-term market changes but which cannot be predicted with certainty;
- The sensitivities are non-linear, and larger or smaller impacts cannot be interpolated or extrapolated from the outcome; and
- The sensitivities assume that all interest and inflation rates move at the same rate at all durations.

C.7.2 Prudent Person Principle

The Company ensures that its assets are invested in accordance with the Prudent Person Principle as set out in Article 132 (Directive 2009/138/EC) through the collective application of its risk policies and business standards. These ensure that the Company invests in assets whose risks it can properly identify, measure, monitor, manage, control and report, and appropriately take into account in the assessment of its overall solvency needs having regard to the term and nature of its liabilities. The Company's Asset Liability Management Business Standard and certain provisions of the Investment Management Business Standard contain mandatory requirements to ensure that the Company develops its own set of key risk indicators and takes into account the risks associated with its investments without relying only on the risk being adequately captured by the capital requirements. Risk appetites by risk type are also set and monitored by the Company. Other business standards set requirements for the quality of investment assets (including setting risk limits to control the market and credit risk within a portfolio), matching of assets to liabilities, diversification of invested assets and use of derivatives.

C.7.3 Additional information on the COVID-19 global pandemic

Further information on the impact of the COVID-19 global pandemic is contained within section F.5.

Aviva Insurance Limited

Solvency and Financial Condition Report 2019

D. Valuation for Solvency Purposes

In this Chapter

- D.1 Assets
- D.2 Technical Provisions
- D.3 Other Liabilities
- D.4 Alternative Methods of Valuation
- D.5 Any Other Information

D. Valuation for Solvency Purposes

The 'Valuation for Solvency Purposes' section of the report provides a description of the bases, methods and main assumptions used in the valuation of assets, technical provisions and other liabilities for each material asset and liability class.

The Company's IFRS balance sheet is presented in column (b) of the following table, in accordance with the classification of assets and liabilities used in its financial statements. The captions used in the table are from the balance sheet QRT S.02.01, rather than the financial statements. The references given in column (a) are to relevant accounting policies and notes provided in the financial statements.

A number of reclassifications, required to align the Company's IFRS balance sheet as shown in its financial statements, to the classifications required for the prescribed format of the SII balance sheet QRT, are given in column (c). The most significant reclassifications are:

- Under the SII Regulations cash flows relating to reinsurance premiums are included within Reinsurance Recoverables, and cash flows relating to premiums and policyholder tax are included within Technical Provisions. In the IFRS balance sheet these amounts are included within reinsurance payables, insurance and intermediaries receivables and other liabilities respectively.
- Loans and amounts receivable from, and payable to, Group companies under IFRS, are reclassified within the SII balance sheet to the relevant underlying nature of the balance. Material amounts have been reclassified as Loans and Deposits from reinsurers.
- Investments, including cash equivalents, are reclassified under SII. They also include accrued investment income which is classified within prepayments and accrued income under IFRS.

The Company's assets and liabilities, as valued under IFRS and reclassified in line with SII Regulations, are shown in column (d). The Company's SII balance sheet is summarised in column (e) and detailed in the balance sheet QRT S.02.01 included in Appendix F.1.1. Differences between the valuation of the Company's assets and liabilities under SII and IFRS are presented in column (f).

Where the valuation of assets and liabilities is the same under IFRS and SII, a description of the bases, methods and main assumptions can be found in the accounting policies and notes of the Company's financial statements. If the valuation is materially different, a description of the bases, methods and main assumptions used under SII is given in Sections D.1, D.2.1 and D.3 below. Where alternative methods of valuation have been used these are detailed in Section D.4.

Assets and other liabilities have been valued, according to the requirements of the SII Regulations, at the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction. The value of other liabilities is not adjusted to take account of the impact of changes in own credit standing of the Company.

The Company applied the following hierarchy of valuation approaches:

- 1. Quoted market prices in active markets for the same assets or liabilities;
- 2. Quoted market prices in active markets for similar assets and liabilities (with adjustments to reflect differences where necessary);
- 3. Alternative methods of valuation.

The Company considers markets to be active where transactions take place with sufficient frequency and volume for pricing information to be available on an ongoing basis. Where the Company has concluded that markets are not active, alternative methods for valuation are used. The assets classified as Level 1 and Level 2 under IFRS 13, are deemed as market consistent under SII. The assets classified as Level 3, for which there is no active market, are considered to use alternative valuation methods under SII.

In line with SII Regulations, the value of the Company's investments in its principal subsidiaries, ACI and AIIDAC, are included within participations in both the SII and IFRS balance sheets. The investments are not disaggregated into ACI and AIIDAC's underlying assets, Technical Provisions and other liabilities. However, when considering the Company's risks and calculating the Company's SCR (unaudited) the underlying risks of ACI and AIIDAC and the Company's other subsidiaries are taken into account.

Balance Sheet – IFRS and SII

As at 31 December 2019 £m	Note in financial statements	IFRS balance sheet classified according to financial statements	Reclassification of IFRS balances to SII balance sheet categories	Reclassified IFRS balance sheet	SII balance sheet	Valuation differences between SII and IFRS
	(a)	(b)	(c)	(d) =(b)+(c))	(e)	(f) =(e)-(d)
Goodwill	M & 10	_	-	-	-	-
Deferred acquisition costs	Y & 18	569	-	569	-	(569)
Prepayments and accrued income	18	129	(129)	-	-	-
Intangible assets	M & 10	137	22	159	-	(159)
Deferred tax assets	CC & 24	64	-	64	71	7
Property, plant and equipment (own use)	N & 12	70	(5)	65	105	40
Property (other than own use)	O & 13	414	-	414	414	-
Participations	C&D &11	1,781	5	1,786	1,227	(559)
Financial investments						
Equities	R & 16	744	(734)	10	10	-
Bonds	R & 16	2,273	22	2,295	2,295	-
Collective investment undertakings	R & 16	698	1,078	1,776	1,776	-
Derivatives	V & 16	151	-	151	151	-
Deposits other than cash equivalents	R & 16	-	42	42	42	-
Loans		-	1,797	1,797	1,797	-
Reinsurance recoverables	L & 23	5,034	(60)	4,974	4,343	(631)
Receivables						
Insurance and intermediaries	S & 17	1,452	(1,449)	3	3	-
Reinsurance	S & 17	23	-	23	23	-
Trade, not insurance	S & 17	34	376	410	410	-
Amounts due from Group companies	S & 17	229	(229)	-	-	-
Loans due from Group companies	S & 17	1,751	(1,751)	-	-	-
Group relief assets	S & 17	142	(142)	-	-	-
Cash and cash equivalents	Z & 31	487	(391)	96	96	-
Other assets	S & 17	115	(57)	58	58	-
Assets		16,297	(1,605)	14,692	12,821	(1,871)
Technical provisions	K & 22	(8,412)	1,434	(6,978)	(6,194)	784
Other provisions	BB & 25	(16)	11	(5)	(5)	-
Deferred tax liabilities	CC & 24	-	-	-	(16)	(16)
Payables and other financial liabilities					()	(10)
Deposits from reinsurers	T & 27	-	(3,080)	(3,080)	(3,080)	-
Derivatives	V & 27	(225)	17	(208)	(208)	-
Debts owed to credit institutions	T & 27	(313)	-	(313)	(313)	-
Financial liabilities other than debts owed to						
credit institutions	T & 27	(40)	-	(40)	(40)	-
Insurance and intermediaries payable	T & 27	(81)	-	(81)	(81)	-
Reinsurance payables	T & 27	(111)	60	(51)	(51)	-
Payables (trade, not insurance)	T & 27	(79)	(340)	(419)	(419)	-
Other payables	T & 27	(19)	19	-	-	-
Amounts due to Group companies	T & 27	(3,323)	3,323	-	-	-
Subordinated liabilities	T & 27	(279)	-	(279)	(279)	-
Current tax liabilities	CC & 24	(16)	16	-	-	-
Other liabilities	28	(739)	145	(594)	(274)	320
Liabilities		(13,653)	1,605	(12,048)	(10,960)	1,088
Excess of assets over liabilities		2,644	-	2,644	1,861	(783)

Accounting Policy F – 'Fair value measurement' and note 15 – 'Fair value methodology' in the Company's financial statements, provide additional information on the fair value of property (other than for own use), financial investments and receivables.

D.1 Assets

Assets have been valued according to the requirements of the SII Directive and related guidance; the basis of the SII valuation principle is the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction. A description of the basis of valuation under SII along with valuation differences between the SII bases and the IFRS financial statements, by asset class, is provided below; if the valuation method has been described in the financial statements or is an alternative method of valuation detailed in Section D.4, it has not been included in this section.

D.1.1 Intangible assets

Intangible assets are valued at £nil under SII.

The intangible assets consist primarily of costs relating to Guidewire, a policy administration and claims handling system.

D.1.2 Deferred acquisition costs

Deferred acquisition costs are recognised under IFRS reporting and deferred to the extent they are expected to be recoverable out of future margins in revenues on those contracts. Under SII these are not recognised and are therefore valued at £nil in the SII balance sheet. The associated cash flows are included in the valuation of SII Technical Provisions.

D.1.3 Deferred tax assets and liabilities

Deferred tax is determined on a non-discounted basis in accordance with International Accounting Standard (IAS) 12, principles on temporary differences between the economic value of assets or liabilities on the SII balance sheet and their tax base.

Assets are recognised to the extent that it is probable that future taxable profits will be available against which they can be utilised. Future taxable profits include taxable liabilities and profits arising from new business. The release of the Risk Margin (unaudited) is not considered to be a source of future profits. Assets are recognised separately to the extent they cannot be offset against corresponding deferred tax liabilities.

The net deferred tax asset arises on unused trading losses and other temporary differences. In addition, the Company has unrecognised gross tax losses (excluding capital losses) of £534m (2018: £275m) to carry forward against future taxable profits. These trading losses have no expiry date.

The Company also has unrecognised capital losses of £232m (2018: £223m). These have no expiry date.

The reduction in value of net deferred tax assets of £9m under SII compared to IFRS arises because deferred tax asset recognition for SII purposes is subject to the more prudent requirements of PRA Supervisory Statement 2/14 compared to the principles of IAS 12 which govern recognition in the financial statements.

A deferred tax liability is recognised on unremitted earnings from overseas subsidiaries and the surplus on the London and Edinburgh Retirement and Death Plan, of which AIL is the principal sponsoring employer.

D.1.4 Property, plant and equipment (own use)

Under IFRS 16, lessees are required to recognise lease assets and liabilities on the statement of financial position for all leases, with the exception of short-term and low-value leases. Where the Company is the lessee, a lease liability equal to the present value of outstanding lease payments and a corresponding right-of-use asset equal to cost are initially recognised. The right-of-use asset is subsequently measured at amortised cost and depreciated on a straight-line basis over the length of the lease term. Depreciation on lease assets and interest on lease liabilities is recognised in the income statement.

Under SII, the leased asset is held at fair value which is deemed to be equal to the related lease liability as the best proxy for fair value.

D.1.5 Property (other than own use)

Investment property held for long-term rental yields and not occupied by the Company is stated at its fair value under IFRS. There is no difference between IFRS and SII valuation basis. Further detail is provided in section D.4.

D.1.6 Participations

Under SII participations are valued, using the adjusted equity method, at the Company's share of the excess of assets over liabilities of each entity, valued on a look through basis to the SII value of the assets and liabilities of the entity. Further detail is provided in section D.4.

Under IFRS, subsidiaries are stated at cost less impairment.

The reduction in value of participations under SII predominantly relates to the Company's investments in ACI, AIIDAC and UKD.

Associates relate to holdings in collective investment undertakings are carried at fair value, as detailed in section D.1.7.

D.1.7 Financial investments

All financial investments, primarily consisting of debt securities, equity securities and unit trusts, are measured at fair value for both SII and IFRS purposes. Fair value is obtained from quoted market prices or, if these are not available, by using relevant valuation techniques. Further information on financial investments valued using an alternative method to either a quoted market price or a quoted market price for a similar asset is included in section D.4.

Listed equity securities, bonds and exchange traded derivatives in the IFRS financial statements are fair valued using quoted market prices. This methodology is consistent with SII. Unlisted equities are fair valued using a range of techniques details which are outlined in section D.4.

Collective investment undertakings are carried at fair value using quoted unit prices which is consistent with SII. The SII valuation of deposits other than cash equivalents is in line with the IFRS treatment.

D.1.8 Reinsurance recoverables

Reinsurance recoverables are calculated as the probability-weighted average of discounted future cash flows relating to reinsurance contracts, adjusted for the expected losses due to counterparty default. Although established separately, reinsurance recoverables are valued on the same basis and using the same methodology and assumptions used to derive Technical Provisions - Best Estimate Liabilities, as described in Section D.2, subject to the following:

- Internal expenses are only allowed if they are recoverable under the reinsurance agreement;
- Where the timing of recoveries diverges from that for payments a separate projection is used;
- Allowance for risk of default depends on the credit rating and exposure to the reinsurance counterparty; and
- Reinsurance assets take into account reinsurance commissions.

Reinsurance recoverables, consistent with the calculation of Technical Provisions - Best Estimate Liabilities, includes expected recoveries from pre-inception contracts where they occur within the premium or claims provisions.

Cash flows relating to future reinsurance arrangements comprise both expected recoveries and expected reinsurance premium payments. This means reinsurance contracts which are expected to be written are taken into account and thus assumptions in relation to the likely future reinsurance purchasing decisions are required.

The material differences between the SII and IFRS valuation bases for reinsurance recoveries are as follows:

- Only reinsurance cash flows relating to long tailed claims reserves are discounted under IFRS whereas all reinsurance cash flows are discounted under SII.
- The rate used to discount PPO cash flows is lower under SII than the equivalent rate used under IFRS.
- The unearned reinsurance premium reserve established under IFRS is replaced with a best estimate reinsurance premium provision. This is offset by the release of deferred reinsurance commissions from other liabilities (see section D.3.2).
- The SII valuation includes the additional reinsurance premium that is expected to be paid for reinsurance to cover business incepted at the valuation date. This is not accounted for under IFRS.

The Company does not have any Special Purpose Vehicles.

D.1.9 Assets arising from leasing arrangements

The Group has a material leasing in respect of property occupied by the Group. Leasing arrangements and the impact of adopting IFRS 16 are detailed in sections A.4.2 and D.10, with further information provided in note 14 to the financial statements.

D.1.10 Changes made to recognition and valuation bases and estimations during the reporting period

Application IFRS 16 has resulted in a reduction in retained earnings of £38m at 1 January 2019. This reflects the fact that the rightof-use assets and lease liabilities amortise to nil at different rates over the lease term. There have been corresponding increases in the value of assets (£68m) and liabilities (£106m), representing the right-of-use assets and liabilities, net of any tax impacts, (note 14 of the Company's financial statements provides further information). The SII treatment of right-of-use assets is detailed in section D.1.4. The adoption of IFRS 16 has had no net effect on the Company's eligible own funds or SCR.

No other material changes were made to the bases used to recognise and value assets, or to their estimations, during the reporting period.

D.2 Technical Provisions

This section provides a definition of SII Technical Provisions, the methodology and main assumptions used in the valuation of the SII Technical Provisions, the total value of SII Technical Provisions split by material lines of business, a comparison of the valuation of SII Technical Provisions with IFRS Technical Provisions and a description of the level of uncertainty in Technical Provisions.

D.2.1 Valuation of Technical Provisions

Technical provisions which comprise Best Estimate Liabilities and a Risk Margin (unaudited) are summarised in the table below. Best estimate liabilities are gross of reinsurance. The figures are also detailed in the QRT S.17.01 (Non-life Technical Provisions) and S.12.01 (Life Technical Provisions), see Appendix F.1.3.

Whilst the Company only conducts non-life and health (similar to non-life) insurance activities, it has material life insurance obligations in the UK in relation to annuities stemming from non-life insurance contracts (PPO). PPO are classified as Technical Provisions - Life (excluding health and index-linked and unit-linked), within the prescribed format of the SII Balance Sheet.

As at 31 December 2019 £m	Best Estimate Liabilities	Risk Margin (unaudited)	Technical Provisions
Line of Business			
Motor vehicle liability	2,278	77	2,355
Other motor insurance	163	4	167
Fire and property damage	676	17	693
General liability insurance	1,932	85	2,017
Other	128	1	129
Non-life insurance obligations	5,177	185	5,362
Health (similar to non-life) insurance obligations	89	3	92
Annuities stemming from non-life insurance	692	49	741
Life insurance obligations	692	49	741
Total	5,957	237	6,195

D.2.1.1 Non-life and health (similar to non-life) Best Estimate Liabilities

The following general principles apply to the valuation of Best Estimate Liabilities for non-life and health (similar to non-life) business:

- A Best Estimate is one that represents the expected outcome from the range of possible outcomes for the future and is reasonable and realistic taking account of all the uncertainties involved;
- A consistent approach has been applied across all non-life and health (similar to non-life) business;
- The calculation of Technical Provisions is performed on a going concern basis. This means that it can be assumed that contracts run to their conclusion and as a result a proportion of expected future costs will be covered by future business; and
- Business written by intermediaries on a delegated authority basis has been included as if written directly by the Company.

The Company's Best Estimate Liabilities are valued based on the present value of future cash flows discounted using relevant riskfree interest rates adjusted for the EIOPA prescribed credit risk adjustment and Volatility Adjustment (see section D.2.4) at the valuation date. The cash flows that are considered when calculating the Best Estimate Liabilities derive from:

- In-force and expired contracts;
- Contracts that have not yet incepted but that the Company has an obligation to enter into at the valuation date (preinception contracts); and
- Future cancellations or endorsements by the policyholder.

Best Estimate Liabilities comprise a claims provision and a premium provision. The claims provision includes cash flows relating to events that occurred before the valuation date, whether reported or not. The cash flows include premiums, net claims costs and expenses. The premium provision includes cash flows relating to future claim events that have not yet occurred, but that are covered by existing contracts and legally binding pre-inception contracts. The cash flows include premiums, net claims and expenses, in respect of future claim events. Where future premium cash flows are expected to exceed projected future claim and expense cash flows, the premium provision is negative.

When modelling these cash flows the inflows are considered separately from the outflows. Claims costs take into account recoveries from salvage and subrogation. Expenses include administrative, investment management, loss adjustment and acquisition expenses including commissions and premium taxes.

Claims costs

The ultimate cost of outstanding claims is estimated using a range of standard actuarial claims projection techniques. The main assumption underlying these techniques is that the Company's past claims experience can be used as a basis to project future claims. Therefore, these methods extrapolate the development of paid and incurred losses, average costs per claim and claim numbers based on the observed development of earlier years. The estimation of ultimate claims costs is done at the level of homogeneous risk groups. These groups are mapped to SII lines of business.

Certain lines of business are also further analysed by claim type or type of coverage. For example, latent claims require specialist actuarial techniques appropriate for the nature of the underlying liabilities. Given the long delay between writing the insurance policy and the claim arising, the techniques used for latent claims typically group claims data by the year claims are reported and project the future number and average cost of claims for homogeneous latent claim types based on a combination of own Company experience and industry-wide data. The Company participates on cross-industry working groups to help inform some of the projection assumptions for latent claims.

Qualitative judgement is used to reflect changes in external factors such as public attitudes to claiming, economic conditions, levels of claims inflation, judicial decisions and legislation, as well as internal factors such as portfolio mix, policy conditions and claims handling procedures.

Premium provisions

Premium provisions are estimated by selecting an exposure measure and using that to establish the unearned and pre-inception exposure. Claims cost projections are set for each future period using trends in historic claims data adjusted for known anomalies in the data that are not expected to be repeated in the future, changes in mix and volume of business and to allow for the impact of projected claims inflation. These cost projections are then applied to the predicted exposure to determine the cash flows.

Expenses

Expenses are adjusted for expense and claims inflation and allocated between the claims and premium provisions. They are analysed by homogeneous risk group or at a minimum by SII line of business. Future administrative costs and commission payments are projected using best estimate expense forecasts. Investment expenses are modelled as a percentage of Technical Provisions. Future unallocated loss adjustment expense provisions are set in relation to expected claims levels.

Events Not in Data (ENID)

ENID are events not deemed to be captured by the data which need to be separately allowed for within the best estimate calculations to take appropriate account of uncertainty. Two types of ENID are considered: "known unknowns", which are possible future scenarios that can be anticipated and "unknown unknowns", which are future scenarios that are completely unexpected. No allowance is made for "unknown unknowns" as by definition, they cannot be known or quantified.

Allowances for "known unknowns" are made using scenario analysis to cover any foreseeable event with a potentially material impact. A core list of events is specified which are considered as the starting point for the analysis. ENID are considered both at SII lines of business level, and at portfolio level with allocations to SII lines of business, depending on the scenario being considered.

Discounting

All cash flows are discounted using the appropriate SII yield curve in the relevant currency. The yield curve is based on the risk free rate at the valuation date and is adjusted for the EIOPA prescribed credit risk adjustment and Volatility Adjustment. Payments are assumed to occur either mid-month or mid-year. Cash flows are modelled in monthly time intervals for the first 10 years and annually thereafter.

Future management actions

There are no future management actions assumed in the calculation of the Company's gross of reinsurance Best Estimate Liabilities as at 31 December 2019.

D.2.1.2 PPO Best Estimate Liabilities

The Company's Best Estimate Liabilities for PPO, in common with non-life business, are valued based on the present value of future cash flows discounted using the relevant risk-free interest rate adjusted for the EIOPA prescribed credit risk adjustment and Volatility Adjustment at the valuation date. The cash flows that are considered when calculating the Best Estimate Liabilities for PPO derive from:

- Payment of claims benefits: with the majority of PPO providing payments relating to care needs of the claimant, with a smaller number providing loss of earnings payments; and
- Expenses: these are relatively small (compared to the size of claims benefits) administrative costs in relation to each PPO.

PPO Best Estimate Liabilities use life insurance actuarial methods and techniques to estimate appropriate assumptions for each individual claimant.

Longevity assumptions

Assumptions are made in relation to future longevity. These assumptions are updated annually and based on the latest general mortality assumptions for the population as a whole (including future expected changes in mortality), as well as any impairment to life expectancy on individual PPO based on independent medical opinions.

Inflation assumptions

PPO payments escalate based on indices specified at the time of settlement of the PPO. The majority of PPO claims escalate based on an Annual Survey of Hours and Earnings index (ASHE) with a smaller number escalating in line with the RPI. Assumptions are therefore required for the future escalation of these indices. The Company assumes that, over the longer term, the future escalation of the ASHE indices will be linked to RPI within the UK economy and uses market consistent views of future RPI inflation as the basis to project future ASHE inflation. Adjustments are then made to allow for any expected differences between future ASHE inflation.

D.2.1.3 Risk Margin (unaudited)

The Risk Margin is an estimate of the amount, in addition to the Best Estimate Liability, that a third party would expect to receive in order to assume ownership of the Company's insurance obligations. The Risk Margin is calculated using a cost of capital approach allowing for diversification between lines of business and is on a net-of-reinsurance basis. The calculation of the Risk Margin is defined as the present value of the cost of capital applied to the SCR (unaudited) in respect of non-hedgeable risks in each future year.

The cost of capital rate is the cost in excess of the risk-free rate, to the third party taking over the liabilities, of raising and holding capital to support the non-hedgeable risks over the lifetime of the business. The same cost of capital rate is used for all insurance companies and is prescribed by EIOPA at 6% per annum.

Discount rate

The rate used to discount the projected non-hedgeable SCR (unaudited) is the basic risk-free rate (including credit risk adjustment), with no allowance for volatility or matching adjustments, where applicable.

Non-hedgeable risk

The SCR (unaudited) in the Risk Margin calculation takes the following risks into account:

- Underwriting risks (non-life, health and life);
- Non hedgeable market risk (except interest rate risk), where it is material;
- Counterparty default risk with respect to reinsurance contracts; and
- Operational risk.

All market risks in respect of investment assets are considered hedgeable. Careful consideration has been given to the extent to which inflation risk in respect of the liabilities should be regarded as hedgeable, consistent with the risk categorisation within the IM. Any inflation risk other than traded price inflation (defined as RPI for UK business and Euro Harmonised Index of Consumer Prices for Irish business) is regarded as non-hedgeable. This includes the excess of claims inflation over traded price inflation, which is considered within the assessment of insurance risk. There is a deep, liquid and transparent market in the UK for instruments whose value is linked to price inflation and so price inflation risk on the opening Best Estimate Liabilities is considered hedgeable. The additional price inflation risk arising from variation from the Best Estimate Liabilities is not however considered hedgeable.

While reinsurance credit risk, and some underwriting risks, may be hedgeable in practice using credit default swaps etc., the Risk Margin calculation assumes that these risks are not hedged after the business is transferred to the third party.

Projection of the non-hedgeable risk SCR (unaudited)

In order to project the non-hedgeable SCR which underpins the Risk Margin, simplifications are selected from the hierarchy set out by EIOPA to ensure that the Risk Margin calculation remains proportionate to the nature, scale and complexity of the business.

The projected risks are then aggregated using a correlation matrix approach at each future time period.

Loss absorbing capacity

The loss absorbing capacity of Technical Provisions assumed in the projection of the non-hedgeable risk SCR (unaudited) is consistent with the loss absorbing capacity of Technical Provisions assumed in the calculation of the SCR (unaudited). No allowance for the loss absorbency of deferred taxes is included in the Risk Margin.

Allocation of the Risk Margin to SII line of business

The Risk Margin is allocated across lines of business using an approximation to the Euler allocation method for IM business units. For SF business units, one of the two prescribed methods is adopted:

- Allocation according to time zero non-hedgeable SCRs (unaudited); or
- Allocation according to present value of non-hedgeable SCRs (unaudited).

Methodology

In projecting the non-hedgeable risk SCR (unaudited), the Company has adopted an enhanced version of the second approach in the EIOPA hierarchy. The SCR (unaudited) is projected by model calculation class and risk category and allows for an increase in relative volatility as the risks run-off to reflect that smaller portfolios are inherently more volatile.

D.2.1.4 Simplifications

Best Estimate Liabilities

In some areas of the calculation of the SII Best Estimate Liabilities, simplified methods have been used. The simplifications used have been assessed and have no material impact on the value of SII Best Estimate Liabilities. Where simplified methods are used, these are documented and justified in the Company's reserving reports and documentation. The main simplifications within the calculation of SII Best Estimate Liabilities are:

• The majority of the Company's Best Estimate Liabilities are in sterling. As part of the calculation of Technical Provisions, the Company segments any material exposure to United States Dollars (USD) and Euro (EUR) currencies. On materiality

grounds, exposure to currencies outside of sterling, USD and EUR are not separately segmented and are instead converted to sterling at prevailing exchange rates.

- Only material inwards reinsurance arrangements are separately modelled.
- The Company's Best Estimate Liabilities include a provision in relation to ENID. For the purposes of discounting cashflows, it is assumed that ENID have the same cashflow profile as other claims.
- Cashflows are modelled in monthly time intervals for the first 10 years and annually thereafter. For the purposes of discounting, all payments are assumed to occur mid-month or mid-year as dictated by the time intervals used.
- When calculating provisions for potential reinsurer default, reinsurance assets are grouped by reinsurer counterparty credit rating and within each credit rating the same probabilities of default are assumed.
- Gross premium debtors are split by class of business and payment date based on the split of written premium.
- The volume of Legally Obliged Unincepted business has been estimated based on a proportion of January's planned written premium for most classes of business. For corporate and speciality type business, the volume has been estimated individually for each class in conjunction with the Group's underwriting teams to allow for business accepted under long-term agreements.

D.2.1.5 Material changes in the relevant assumptions compared to the previous reporting period

There were no material changes in the relevant assumptions made in the calculation of Technical Provisions compared to the previous reporting period, other than in relation to Ogden rate, as detailed in section D.2.2.

D.2.2 Level of uncertainty

The actual cost of settling insurance obligations may differ from the Best Estimate Liabilities because experience may be worse than assumed or future claims inflation may differ from that expected. There are a number of potential developments that would have a material adverse impact on the Best Estimate Liabilities value including:

- Catastrophic weather events;
- New types of latent claims;
- Unanticipated legislative changes; and
 Unanticipated inflation.

Specific areas of uncertainty are:

- In conducting its insurance business, the Company receives general insurance liability claims, and becomes involved in actual or threatened related litigation arising therefrom, including claims in respect of pollution and other environmental hazards. Amongst these are claims in respect of asbestos production and handling. Given the significant delays that are experienced in the notification of these claims, the potential number of incidents which they cover and the uncertainties associated with establishing liability, the ultimate cost cannot be determined with certainty. Gross of reinsurance the level of uncertainty within the Technical Provisions for latent claims is high. The Company has extensive reinsurance in place against these claims so net of reinsurance the level of uncertainty is insignificant.
- PPOs represent a material part of Best Estimate Liabilities. They also represent one of the most uncertain elements of the Company's Technical Provisions due to their long-tailed nature and the sensitivity to changes in economic-related assumptions. Additional uncertainty arises due to potential differences in the life expectancy of claimants compared to that expected, as well as the potential uncertainty in the propensity for non-life large injury claims to settle as PPOs as opposed to lump sum awards. Gross of reinsurance the level of uncertainty within the Technical Provisions for PPOs is very high. The Company purchases reinsurance to mitigate longevity risk in relation to these claims, which materially reduces the level of uncertainty.
- Following the announcement of the Lord Chancellor on 15 July 2019 to increase the Ogden discount rate from the minus 0.75% set in 2017 to minus 0.25%. The July 2019 announcement is considered to reduce uncertainty within the shorter term, however uncertainty does remain in the medium to longer term as the Lord Chancellor will review the Ogden discount rate at least every five years and has also asked for further review on the advantages and disadvantages of a dual rate regime.
- The UK's decision to exit the EU increases the uncertainty within the valuation process, mainly in relation to future claims ratio forecasts. This is driven by increased uncertainty around the economic outlook for the UK including inflation expectations, economic activity, unemployment levels and the future strength of sterling against other currencies. There's also uncertainty regarding whether the UK is now more likely to introduce legislative changes which have the potential to impact claims costs. Most lines of business have the potential to be impacted.
- Further information on the impact of the COVID-19 global pandemic is contained within section F.5 (unaudited).

D.2.3 Material differences between the SII and IFRS valuation bases

The following table summarises gross of reinsurance SII Technical Provisions by material line of business and compares these to IFRS reclassified Technical Provisions. The information contained in this table is an extract from the SII Balance Sheet QRT S.02.01, presented in Appendix F.1.1.

echnical Provisions as at 31 December 2019 £m	Best Estimate Liabilities	Risk Margin (unaudited)	Technical Provisions	IFRS reclassified Technical Provisions	Difference between SII and IFRS reclassified Technica Provision
Non-life insurance obligations	5,177	185	5,362	6,138	(776)
- Motor vehicle liability	2,278	77	2,355	2,511	(156)
- Other motor insurance	163	4	167	253	(85
- Fire and property damage	676	17	693	965	(272
- General liability insurance	1,932	85	2,017	2,225	(208
- Other	128	1	129	184	(54
Health (similar to non-life) insurance obligations	89	3	92	160	(68)
Life insurance obligations	692	49	741	680	6
Total	5,957	237	6,195	6,978	(783)

On materiality grounds the Other Non-life row of this table groups together a number of the smaller non-life lines of business.

The material differences between the SII and IFRS valuation bases are summarised below:

- SII Technical Provisions include the Risk Margin (unaudited), which is not included within IFRS Provisions, and which
 increases SII Technical Provisions compared to IFRS Provisions. This impacts on all lines of business, but has the greatest
 impact on the Life, Motor Vehicle Liability and General Liability insurance lines of business;
- An explicit margin for uncertainty is included within IFRS Provisions but removed under SII. This impacts all lines of business and reduces SII Technical Provisions compared to IFRS Provisions;
- Only long-tailed claims reserves (predominantly latent claims within General Liability insurance and PPO claims) are
 discounted within IFRS Provisions, whereas all cash flows are discounted under SII. This difference reduces SII Technical
 Provisions compared to IFRS Provisions and affects all lines of business, but with the most material impact on the Motor
 Vehicle Liability and General Liability insurance lines of business given these classes typically contain longer duration cash
 flows which see relatively larger impacts from discounting under SII;
- The rate used to discount cash flows for PPO claims within IFRS Provisions is higher than that used under SII. This increases SII Technical Provisions compared to IFRS Provisions and impacts the Life line of business which contains the Company's PPO claims in payment, as well as the Motor Vehicle Liability and, to a lesser extent, General Liability insurance lines of business which include provisions for claims which are expected to settle as PPO claims in the future;
- The rate used to discount cash flows for latent claims within IFRS provisions is lower than that used under SII, which reduces SII Technical Provisions compared to IFRS provisions. This impacts the General Liability insurance line of business;
- The unearned premium reserve established under IFRS for all Non-life and Health lines of business is replaced with a Best Estimate premium provision which incorporates the expected cost of claims and expenses on the unearned periods of exposure. This typically leads to a lower premium provision under SII than the equivalent unearned premium reserves under IFRS. This difference impacts all non-life and health lines of business, but has proportionately larger impacts on the Fire and Property Damage and other non-life lines of business; and
- Under SII, provisions are established for Legally Obliged Unincepted Business, whereas these provisions are not included within the IFRS valuation basis. This difference impacts all Non-life and Health lines of business. This will reduce SII Technical Provisions compared to IFRS Provisions.

D.2.4 Volatility Adjustment

The Volatility Adjustment removes temporary distortions in spreads caused by illiquidity in the market or extreme widening of credit spreads, in particular in relation to government bonds. The PRA has approved the Company's application to apply a Volatility Adjustment (PRA reference number: 2191473). The impact of the Volatility Adjustment on Technical Provisions, Basic Own Funds, Eligible Own Funds to meet the SCR, the SCR (unaudited), Eligible Own Funds to meet the Minimum Capital Requirement (MCR) and the MCR is detailed in the Long Term Guarantees and Transitional measures QRT S.22.01 (see Appendix F.1.5). The impact of removing the Volatility Adjustment from gross SII Technical Provisions would be to increase their value by £58m.

D.2.5 Other reliefs

No transitional provisions have been applied in the calculation of SII Technical Provisions.

D.3 Other Liabilities

Other liabilities have been valued according to the requirements of the SII Directive and related guidance; the basis of the SII valuation principle is the amount for which they could be exchanged between knowledgeable willing parties in an arm's length transaction. A description of the basis of valuation under SII along with valuation differences between the SII bases and the IFRS financial statements, by material class, is provided below; if the valuation method has been described in the financial statements or is an alternative method of valuation detailed in Section D.4, it has not been included in this section.

The Company's financial statements provide information about contingent liabilities and other risk factors in note 29. The Company has no additional material contingent liabilities to recognise under SII.

D.3.1 Payables and other financial liabilities

Payables and other financial liabilities are recognised initially at their fair value and are subsequently measured at amortised cost using the effective interest rate method, under IFRS. There are no material differences between the IFRS value and fair value under SII.

D.3.2 Other liabilities

Reinsurers' share of deferred acquisition costs of £291m and deferred income of £31m, included within other liabilities under IFRS, are not recognised and therefore valued at £nil in the SII Balance Sheet.

Material differences in the valuation of Technical Provisions are explained in Section D.2.3.

There are no other material differences between the IFRS and SII valuation bases.

D.3.3 Liabilities arising from leasing commitments

Leasing arrangements and the impact of adopting IFRS 16 are detailed in sections A.4.2 and D.1.10, with further information on future contractual aggregate minimum lease payment commitments under non-cancellable operating leases provided in note 14 to the financial statements.

D.3.4 Assumptions, judgements and uncertainty

No material assumptions or judgements were applied to, nor is any material uncertainty associated with, the recognition and valuation of other liabilities.

D.3.5 Changes made to recognition and valuation bases and estimations during the reporting period

The Company adopted IFRS 16 with effect from 1 January 2019. The impact of this is detailed in section D.1.10. No other material changes were made to the bases used to recognise and value other liabilities, or to their estimations, during the reporting period.

D.4 Alternative Methods of Valuation

The majority of the Company's assets and other liabilities are valued using quoted market information or observable market data. Maximum use has been made of market observable inputs when alternative methods of valuation have been adopted. The material assets and other liabilities, disclosed in the Balance Sheet QRT in Appendix F.1.1, that have alternative methods of valuation methods applied are as follows:

Participations

Participations of £1,178m are valued at the Company's proportionate equity share of the excess of assets over liabilities of each subsidiary, valued on a look through basis to the SII value of the assets and liabilities of the entity. This method is used because quoted prices from active markets in the equity of the subsidiaries are not available. The Company's investment in participations largely relates to its principal subsidiary ACI. Most of ACI's assets and liabilities are valued using quoted market information or observable market data. However, ACI values net Defined Benefit Obligations of £77m in accordance with the requirements of IAS19: Employee Benefits. The present value of future benefits is determined by projecting members' entitlements to the assumed retirement age. Expected payments are discounted to the valuation date reflecting future interest rates and mortality.

Property, plant and equipment (for own use)

Property held for own use includes leased assets that are measured at amortised cost and depreciated on a straight-line basis over the length of the lease term. Under SII, the leased asset is held at fair value which is deemed to be equal to the related lease liability. The lease liability is equal to the minimum lease payments, consisting of future expected cashflows discounted using the interest rate implicit in the lease. This approach means that the uncertainty relating to the valuation of property (other than own use) net of lease liabilities is immaterial.

Property (other than for own use)

Property (other than for own use) of £414m is recognised at its fair value as assessed by qualified external valuers using a discounted cash flow approach. The valuation uncertainty of investment property has been assessed by reference to a study of sales prices achieved in commercial real estate transactions against their previous valuations. This assessment indicates that the uncertainty relating to the valuation of property (other than own use) is immaterial.

Property funds

Collective investment undertakings include property funds of £154m. The underlying properties are valued based on external valuation reports received from fund managers. As with directly held property, the underlying properties are valued by third party surveyors using a discounted cash flow approach. An assessment of the valuation uncertainty of property funds was completed reviewing secondary prices where available and reviewing the underlying property elsewhere, consistent with the assessment of directly held property. This indicated that the valuation uncertainty is immaterial.

Loans receivable

Loans receivable, of £1,797m under SII, principally comprise the Company's loans to its immediate parent AGH of £1,267m and the subordinated loans to its subsidiary ACI of £204m and £279m. The SII value of loans receivable includes accrued interest of £46m which is classified as accrued income under IFRS. These loans are valued using an income approach, which reflects the present value of contractual cash flows using discount rates calibrated as far as possible to relevant market observable parameters and taking into account any embedded features of the loan. The valuation uncertainty associated with loans receivable is considered to be immaterial.

Subordinated loan payable

The subordinated loan payable to AGH is valued at £279m (translated from CAD480m at the year-end exchange rate) using an income approach which reflects the present value of contractual cash flows using discount rates calibrated as far as possible to relevant market observable parameters and taking into account any embedded features of the loan. In accordance with SII guidance, the discount rate is not adjusted for changes in credit risk of the borrower. The absolute valuation uncertainty associated with the subordinated loan payable is immaterial.

Derivatives

Derivative assets and liabilities, with SII values of £151m and £208m respectively, are stated at fair value under IFRS and SII but include accrued income under SII. This is classified separately under IFRS. The majority of derivatives are over-the-counter derivatives and are valued by the broker based on an income approach using either discounted cash flow models or option pricing models and applying market observable inputs. The valuations are validated against counterparty statements. The absolute valuation uncertainty associated with derivatives is immaterial.

Adequacy of valuation compared to experience

The Company operates independent price verification (IPV) controls across all assets. For asset types where a secondary source is available (such as over-the-counter derivatives and publicly traded bonds), this involves comparing the primary valuation to a secondary independent source, investigating material differences and making a valuation adjustment where appropriate.

For asset classes where a secondary source is not available and there is no secondary trading activity (such as property (other than for own use) and private equity), the Company relies on the implementation of accepted valuation standards by parties independent of the Group (e.g. valuation of investment property in line with the methodologies described in the RICS "red book"). These are asset classes with considerable valuation uncertainty and to assess the reasonableness of the valuations back testing analysis is performed on an annual basis for any assets sold during the year. Results of these back-testing analyses are presented in the Company's valuation uncertainty assessments.

D.5 Any Other Information

D.5.1 Additional information on the COVID-19 global pandemic (unaudited)

Further information on the impact of the COVID-19 global pandemic is contained within section F.5.

Aviva Insurance Limited

Solvency and Financial Condition Report 2019

E. Capital Management

In this Chapter

- E.2 Solvency Capital Requirement (unaudited) and Minimum Capital Requirement
- E.3 Use of the duration-based equity risk sub-module in the calculation of the Solvency Capital Requirement (unaudited)
- E.4 Differences between the Standard Formula and any Internal Model used
- E.5 Non-Compliance with the Minimum Capital Requirement and Non-Compliance with the Solvency Capital Requirement (unaudited)
- E.6 Any Other Information

E.1 Own Funds

E. Capital Management

The 'Capital Management' section of the report describes the objectives, policies and procedures employed by the Company for managing its Own Funds. The section also covers information on structure and quality of Own Funds and calculation of SCR (unaudited), including information about the Company's IM.

E.1 Own Funds

E.1.1 Management of Own Funds

The Company's capital and risk management objectives are closely interlinked and support earnings growth and dividend policy, whilst also recognising the critical importance of protecting policyholder and other stakeholder interests. The Company's primary objective of managing capital efficiently is to optimise the balance between return and risk, whilst maintaining economic and regulatory capital surplus in accordance with approved risk appetites.

In managing its Own Funds the Company also seeks to:

- Match the profile of its assets and liabilities, taking account of the risks inherent in the business;
- Maintain sufficient, but not excessive, financial strength to support new business growth and satisfy the requirements of its policyholders and its regulator, the PRA;
- Retain financial flexibility by maintaining sufficient liquidity; and
- Allocate capital efficiently, applying it to support value-adding growth and repatriating excess capital to its shareholder through dividends.

Own Funds are monitored via forecasts over a three year planning horizon. A number of stress and scenario tests are used to enable the Company to understand the volatility of its earnings and capital requirement, and therefore manage its capital more efficiently.

There have been no material changes in the objectives, policies or processes employed for managing Own Funds during the year.

E.1.2 Eligible Own Funds

An analysis of the Company's Own Funds by tier is presented in the Own Funds QRT S.23.01.01, (see Appendix F.1.6), and summarised below.

Own Funds £m	Total	Tier 1 (unrestricted)	Tier 2	Tier 3	Total	Tier 1 (unrestricted)	Tier 2	Tier 3
As at 31 December	2019	2019	2019	2019	2018	2018	2018	2018
Ordinary share capital	204	204	-	-	204	204	-	-
Reconciliation reserve	1,586	1,586	-	-	1,432	1,432	-	-
Subordinated loan	279	-	279	-	276	-	276	-
An amount equal to net deferred tax assets	71	-	-	71	77	-	-	77
Total Basic Own Funds	2,140	1,790	279	71	1,989	1,636	276	77

Tiering analysis

The Company's ordinary share capital and reconciliation reserve are available to absorb losses and have the Tier 1 features of permanence and subordination. As the Company's Articles of Association do not contain any restriction on the right of the Company to cancel dividends or other distributions at any time before they are paid, the Company's ordinary share capital is classified as unrestricted Tier 1.

The Company's subordinated loan from AGH has the Tier 2 features of subordination and duration, as detailed below.

An amount equal to the value of net deferred tax assets is classified as Tier 3, as prescribed by the SII Regulations.

Subordinated loan

The Company has a subordinated unsecured loan arrangement from AGH of CAD 480m. The loan accrues interest at 474 basis points above the Canadian Dealer Offered Rate and matures in 2046. The table below sets out the value of the subordinated loan:

	£m	£m
As at 31 December	2019	2018
Unsecured loan arrangement from AGH	279	276
Total unsecured loans	279	276

Significant changes in Own Funds during the year

Tier 1 Own Funds of £1,790m (2018: £1,636m) increased by £154m during the year. The increase was mainly driven by capital generated from the Company's operations partly offset by dividends paid of £80m.

Dividends of £359m were approved by the Board in December 2018 and paid in February 2019. Under SII regulations they were incorporated in Own Funds as a foreseeable dividend as at 31 December 2018. In February 2020 the directors declared interim dividends of £224m. These were not approved in 2019 and as such do not represent foreseeable dividends as at 31 December 2019. The reconciliation reserve, detailed in the following section, shows the adjustment for foreseeable dividends.

The Company did not issue or redeem any Own Fund items in the year.

Reconciliation reserve

The Company's capital comprises ordinary share capital, capital reserves and retained earnings. Capital reserves and retained earnings are not separately disclosed in Own Funds. They are notionally included in the reconciliation reserve, which reconciles the total excess of assets over liabilities with identifiable capital instruments included in Own Funds.

The table below sets out the constituent parts of the reconciliation reserve:

	£m	£m
As at 31 December	2019	2018
SII excess of assets over liabilities	1,861	2,072
Foreseeable dividend	-	(359)
Ordinary share capital	(204)	(204)
An amount equal to net deferred tax assets	(71)	(77)
Reconciliation reserve	1,586	1,432

Eligibility of tiered capital

The eligibility of tiered capital, to cover the SCR (unaudited) and MCR depends upon the tiering shown above and a number of quantitative limits. The Company's Own Funds satisfy all limits applicable to the SCR (unaudited) and therefore the eligibility of the Company's capital to cover the SCR (unaudited) is unrestricted.

At least 80% of the MCR must be covered by Tier 1 capital and Tier 3 capital is not eligible to cover the MCR at all. As a result eligible funds to meet the MCR are restricted, as shown in the table below.

	£m	£m
As at 31 December	2019	2018
Total eligible Own Funds to meet the SCR	2,140	1,989
Total eligible Own Funds to meet the MCR	1,873	1,710

The ratio of eligible Own Funds to the SCR (unaudited) and the MCR is detailed below.

As at 31 December	2019	2018
Ratio of eligible Own Funds to the SCR	186%	158%
Ratio of eligible Own Funds to the MCR	450%	465%

E.1.3 Material differences between equity on an IFRS basis and Own Funds

The Company's Own Funds are equal to the excess of assets over liabilities on a SII basis plus the subordinated loan as set out in the following table.

	£m	£m
As at 31 December	2019	2018
Excess of assets over liabilities on a SII basis	1,861	2,072
Foreseeable dividend	-	(359)
Subordinated loan	279	276
Own Funds	2,140	<i>1,989</i>

The Company's excess of assets over liabilities on a SII basis was £783m (2018: £706m) less than its total equity on an IFRS basis. The following table details the material differences between the excess of assets over liabilities on a SII basis and total equity on an IFRS basis.

As at 31 December 2018	£m	£m	See Section
Total equity on an IFRS basis		2,644	
Elimination of goodwill and other intangible assets	(159)		D.1.1
Elimination of deferred acquisition costs	(569)		D.1.2
Valuation adjustments to investments in participations	(559)		D.1.6
Valuation adjustments to property, plant and equipment (own use)	40		D.1.4
Valuation adjustments to reinsurance recoverables	(631)	-	D.1.8
Valuation adjustments to Technical Provisions	784		D.2.3
Valuation adjustments to other liabilities	320		D.3.2
Net deferred tax adjustments	(9)	-	D.1.3
		(783)	
Excess of assets over liabilities on a SII basis		1,861	

E.1.4 Transitional arrangements and restrictions

The Company's Own Funds are unrestricted and fully transferable.

E.2 Solvency Capital Requirement (unaudited) and Minimum Capital Requirement

E.2.1 The amount of the SCR and MCR

The Company's SCR as at 31 December 2019 was £1,148m (2018: £1,258m). This is shown in the SCR QRT, S.25.02, see Appendix F.1.7.

The Company's MCR as at 31 December 2019 was £416m (2018: £368m). This is shown on the MCR QRT, S.28.01, see Appendix F.1.8.

The final amount of the SCR is subject to supervisory assessment and does not include any regulator-imposed capital add-ons.

E.2.2 The composition of the SCR

The Company determines its SCR using a PIM. The SCR of the IM component, the SF component and the diversification benefit between the two is shown below:

	£m	£m
As at 31 December	2019	2018
IM component	1,089	1,206
SF component	90	81
Diversification between the IM and SF components	(31)	(29)
Total SCR	1,148	1.,258

The SCR comprises the material risk categories shown in the following table. This combines the IM and SF components. Further detail is shown in the SCR QRT S.25.02.

Diversified SCR by material risk category (per the SCR QRT)	£m	£m
As at 31 December	2019	2018
Market risk	768	784
Non-life underwriting risk	686	838
Operational risk	358	370
Counterparty risk	101	103
Other	(19)	(47)
Diversification between risk categories	(747)	(790)
Total SCR	1,148	1,258

Diversification benefits between risks are primarily driven by the relative size of risks and the correlations between them. For example, two risks diversify more if they are similarly sized and diversify less the more highly correlated they are. Diversification is also influenced by the shape of risk distributions, in that risks where extreme events are more likely tend to diversify better. The diversification benefit of £747m (2018: £790m) in the table above is the diversification between the risk categories listed in the table. In addition, each risk category includes the impact of diversification within that risk. For example, the non-life underwriting risk includes underwriting and reserve risk along with the diversification between them.

E.2.3 Simplifications, undertaking specific parameters and matching adjustment (unaudited)

Where the SCR is calculated using the SF, the SII regulations specify 23 simplified calculations that may be used across all the SF risk modules except operational risk. The use of these simplifications is disclosed in QRT S.25.02.21 (Appendix F.1.7), where applicable. The Company has not used any of these simplified calculations to calculate the SCR at 31 December 2019.

Where the SCR is calculated using the SF, the SII Regulations specify certain undertaking-specific parameters that may be used in place of the standard parameters, subject to regulatory approval. These are available for non-life (including some health) premium and reserve risks. The use of these undertaking-specific parameters must be disclosed in QRT S.25.02.21 (Appendix F.1.7), where applicable. The Company has not used any undertaking-specific parameters to calculate the SCR at 31 December 2019.

E.2.4 MCR calculation

The Company's MCR is calculated by applying prescribed factors to its written premium and its net Best Estimate Liabilities. In accordance with the SII Regulations, premium and Best Estimate Liabilities of subsidiary companies are not included in the calculation. The MCR is subject to two further constraints: it must lie in the range of 25% to 45% of the Company's SCR; and it cannot be less than an absolute minimum of ≤ 3.7 m, translated to ± 3.2 m for the year ended 2019 (*2018: \pm 3.3m*). The Company's MCR currently lies within this range.

E.3 Use of the duration-based equity risk sub-module in the calculation of the Solvency Capital Requirement (unaudited)

The Company does not use the duration-based equity risk sub-module in the calculation of the Company's SCR.

E.4 Differences between the Standard Formula and any Internal Model used (unaudited)

E.4.1 Key uses of the IM

The IM provides input to a number of key business processes and activities. Therefore, the outputs from the IM are used in day-today risk management and business decisions across the Company. "Use" does not imply that the IM is used to directly run the business, but rather that the outputs of the IM and the IM itself are used to support decision-making, whilst acknowledging its limitations and balancing against other elements of the Risk Management Framework.

The primary purpose of the Company's IM is to calculate the capital metrics, principally the SCR (unaudited), required for regulatory reporting under SII. The outputs of the Company's IM are also used in risk-based performance reporting and risk and financial strength reporting to senior management, the Board, the shareholder and rating agencies.

The granular metrics produced by the IM are used in setting the Company's strategy and support a series of other activities including:

- Business planning, capital allocation, measurement of the risk-adjusted return and setting risk appetites;
- Improving pricing and product design by assessing the level of capital required to support different types of product;
- Assessing the appropriateness of potential acquisitions or business investments through the impact on surplus capital;
- Identifying the need for targeted reinsurance contracts to mitigate undesirable risk exposures, through modelling
 potential adverse scenarios; and
- Measuring the impact of market changes on assets and liabilities to drive investment strategy.

E.4.2 Scope of the IM and integration into the SF to derive the PIM

The Company uses a PIM to calculate its SCR (unaudited). The IM component covers all of the Company's risk categories and takes into account the underlying risks of the Company's subsidiaries, subject to the exclusions detailed below.


The SCR is calculated using SF for the following elements of the Company's business:

- Private medical insurance business;
- ACI's staff pension fund;
- Some of the Company's non-insurance participations; and
- Business underwritten by the Company's subsidiaries, AIIDAC and Gresham, to the extent it has not been reinsured to the Company.

The Company has chosen to use Integration Technique 2 within Method 2 as detailed in Annex XVIII of the SII Delegated Regulations, to combine the results of its IM and SF calculations. This technique requires specifying upper and lower bounds for correlations between the entire IM block and each of the SF risk modules. A correlation matrix is then constructed with correlations between these bounds such that it maximises the Basic Solvency Capital Requirement.

E.4.3 Method used in the IM for calculating the probability distribution forecast

The purpose of the IM is to identify the risks to which the Company is exposed, model these risks using suitably calibrated inputs and aggregate them to compute the SCR (unaudited). An overview of the Company's approach is shown below.



The Company's IM allows flexibility in determining which statistical distributions to use to represent risk factors. This flexibility is important as it ensures that the behaviour of the most important risks to the Company is modelled appropriately.

For the market risk factors standard statistical distributions are used which are fitted via the standard risk factor calibration process. However, for other risk types, such as non-life underwriting and operational risk, distributions are derived from further modelling processes. This approach is appropriate given both the materiality of these risk types and the desire to ensure the risk's behaviour is adequately captured.

The Company uses a wide range of testing and review processes to ensure that the calibrations are appropriate and the IM outputs are reasonable. These range from bottom-up reviews of the material assumptions used in the modelling process and the testing of the calibrations and loss functions, to top-down stress and scenario testing, back testing and benchmarking.

Risk measure and time period used in the IM

The IM produces an aggregate distribution of the change in Basic Own Funds over a one-year time horizon from which the SCR (unaudited) can be directly derived, in line with Article 101 of the SII Directive. The SCR (unaudited) is the 99.5th percentile.

E.4.4 Material differences between the SF and IM methodologies and assumptions

The key difference between SF and the IM is that the IM has been tailored to the Company's risk profile. The IM calibrates a distribution of losses for each risk and uses these, together with a set of correlations between these risks, to derive a joint distribution of losses for the Company. The SCR (unaudited) is derived from this and ensures the Company holds sufficient capital to withstand a 1 in 200 event over one year. Calibrating risks for the IM therefore requires detailed data analysis and use of statistical models. SF simply uses prescribed formulae to calculate the capital required for each risk exposure.

Material differences between the SF and IM methodologies and assumptions by risk type are:

Market risk

- The Company's IM includes the risk on sovereign bonds, which is not included in SF; and
- In the Company's IM interest rates are modelled in more detail to ensure changes in the slope and shape of the yield curve are captured. SF only considers the change in the level of interest rates.

Non-life underwriting risk

- Risks relating to latent claims and PPO are included in the IM using the Company's specific risk distributions. As SF does not explicitly address latent claims and PPO, a company using SF would need to devise undertaking specific parameters;
- Man made catastrophes are allowed for in the IM as an ENID, using Company-specific parameters and taking into account diversification benefits. SF computes the impact of man made catastrophes formulaically;
- In SF the impact of inflation is implicitly captured in the calibration of the premium and reserve risks. The Company's IM separately identifies and calibrates RPI movements that can be traded;
- The Company's IM employs a finer level of granularity for material lines of business which allows for more distinction between material product types and in particular between commercial and personal lines which are grouped in SF; and
- The Company's IM captures risks where the probability of extreme values is higher than normal, for example, PPO related to large personal injury claims. SF would not adequately capture the impact of these elements for the Company.

Operational risk

• The Company's IM assesses operational risk using a scenario based approach. SF uses a simple formulaic approach.

Counterparty risk

- SF considers all counterparty default risk under one module. The Company's IM takes into account both the type of the counterparty and the nature of the exposure; and
- The Company's IM considers default risk in more detail, taking into account spread risks and diversification between various credit exposures. SF does not consider these elements.

Aggregation, diversification and tax

- The Company's IM allows it to determine diversification at a more granular level and capture important features such as its geographical diversification;
- The Company's IM uses explicit correlation matrices to combine sub-module losses within each risk module, and then to combine the calculated losses of the different risk modules. The SF uses a simpler hierarchical correlations approach; and
- The Company's IM assesses loss functions net of tax. The SF calculation requires tax relief to be deducted from the gross SCR.

E.4.5 Data used in the IM

The data used in the Company's IM includes:

- Accounting data, computed on an IFRS basis, which is used in the valuation of assets and liabilities;
- Policy data from both policies in force and past policies that includes premium data, historic data on claims and exposure
 data covering potential catastrophic events such as on geographical concentrations;
- Operational risk data obtained from an external database covering industry operational risk losses, which is obtained from the Operational Risk Insurance Consortium;
- Financial market data, including asset data externally obtained such as from FTSE 100 index;
- Asset data including the market value of assets, most often derived from the accounting data; and
- Other data including numerical, census or classification information, but excluding qualitative information.

The SII Data Governance Group Business Standard establishes the control environment and the criteria to be used to assess the quality of the data in terms of appropriateness, completeness, accuracy, and consistency before using it for the SCR calculation.

E.5 Non-Compliance with the Minimum Capital Requirement and Non-Compliance with the Solvency Capital Requirement (unaudited)

The Company has complied continuously with both the MCR and the SCR (unaudited) throughout the reporting period.

E.6 Any Other Information

E.6.1 Additional information on the COVID-19 global pandemic (unaudited)

Further information on the impact of the COVID-19 global pandemic is contained within section F.5.

Aviva Insurance Limited

Solvency and Financial Condition Report 2019

F. Appendices

In this Section

F.0 Cautionary Statement

F.1	Public Disclosure Quantitative Reporting Templates	
F.1.1	S.02.01 Balance Sheet	Part-Audited
F.1.2.1	S.05.01 Premium claims and expenses (by line of business) [life]	Non-Audited
F.1.2.2	S.05.01 Premium claims and expenses (by line of business) [non-life]	Non-Audited
F.1.2.3	S.05.02 Premium claims and expenses (by country) [life]	Non-Audited
F.1.2.4	S.05.02 Premium claims and expenses (by country) [non-life]	Non-Audited
F.1.3.1	S.12.01 Technical Provisions [life]	Part-Audited
F.1.3.2	S.17.01 Technical Provisions [non-life]	Part-Audited
F.1.4	S.19.01 Insurance claims [non-life]	Non-Audited
F.1.5	S.22.01 Impact of transitional measures	Audited
F.1.6	S.23.01 Own Funds	Audited
F.1.7	S.25.02 Solvency Capital Requirement	Non-Audited
F.1.8	S.28.01 Minimum Capital Requirement	Part-Audited

- F.2 Glossary of Abbreviations and Definitions
- F.3 Directors' Statement
- F.4 Auditors' Report
- F.5 Additional information on the COVID-19 global pandemic

Non-Audited

F.0 Cautionary Statement

This announcement contains, and we may make other verbal or written 'forward-looking statements' with respect to certain of the Company's plans and current goals and expectations relating to future financial condition, performance, results, strategic initiatives and objectives. Statements containing the words 'believes', 'intends', 'expects', 'projects', 'plans', 'will', 'seeks', 'aims', 'may', 'could', 'outlook', 'likely', 'target', 'goal', 'guidance', 'trends', 'future', 'estimates', 'potential' and 'anticipates', and words of similar meaning, are forward-looking. By their nature, all forward-looking statements involve risk and uncertainty. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in these statements.

The Company believes factors that could cause actual results to differ materially from those indicated in forwardlooking statements in the announcement include, but are not limited to: the impact of ongoing difficult conditions in the global financial markets and the economy generally; the impact of simplifying our operating structure and activities; the impact of various local and international political, regulatory and economic conditions; market developments and government actions (including those arising from the outcome of the negotiations on the future economic relationship between the UK and the EU); the effect of credit spread volatility on the net unrealised value of the investment portfolio; the effect of losses due to defaults by counterparties, including potential sovereign debt defaults or restructurings, on the value of our investments; changes in interest rates that may reduce the value of our portfolio; the impact of changes in short or long-term inflation; the impact of changes in equity or property prices on our investment portfolio; fluctuations in currency exchange rates; the effect of market fluctuations on the value of the assets backing reserves; the amount of allowances and impairments taken on our investments; the effect of adverse capital and credit market conditions on our ability to meet liquidity needs and our access to capital; changes in, or restrictions on, our ability to initiate capital management initiatives; changes in or inaccuracy of assumptions in pricing and reserving for insurance business (particularly with regard to policy renewal rates), a cyclical downturn of the insurance industry; the impact of natural and man-made catastrophic events (including the impact of COVID-19) on our business activities and results of operations; our reliance on information and technology and third-party service providers for our operations and systems; the inability of reinsurers to meet obligations or unavailability of reinsurance coverage; increased competition in the UK and in other countries where we have significant operations; the impact of actual experience differing from estimates used in valuing and amortising deferred acquisition costs ('DAC'); the impact of recognising an impairment of our goodwill or intangibles with indefinite lives; changes in valuation methodologies, estimates and assumptions used in the valuation of investment securities; the effect of legal proceedings and regulatory investigations; the impact of operational risks, including inadequate or failed internal and external processes, systems and human error or from external events (including cyber attack); risks associated with arrangements with third parties; our reliance on third-party distribution channels to deliver our products; funding risks associated with our participation in defined benefit staff pension schemes; the failure to attract or retain the necessary key personnel; the effect of fluctuations in share price as a result of general market conditions or otherwise; the effect of simplifying our operating structure and activities; the effect of a decline in any of our ratings by rating agencies on our standing among customers, broker-dealers, agents, wholesalers and other distributors of our products and services; changes to our brand and reputation; changes in government regulations or tax laws in jurisdictions where we conduct business; the inability to protect our intellectual property; the policies, decisions and actions of government or regulatory authorities in the UK, the European Union, the US or elsewhere, including the implementation of key legislation and regulation. For a more detailed description of these risks, uncertainties and other factors, please see the Aviva plc Annual report and accounts.

The Company undertakes no obligation to update the forward-looking statements in this announcement or any other forward-looking statements it may make. Forward-looking statements in this report are current only as of the date on which such statements are made.

This Solvency and Financial Condition Report has been published for information only, it is based on our understanding as at 7 April 2020 and does not provide financial or legal advice. Other than as set out in section F.3 (Directors Statement), the Company, its directors, employees, agents or advisers do not accept or assume responsibility to any person to who this document is shown or into whose hands it may come, and any such responsibility or liability is expressly disclaimed.

Appendix F.1.1 S.02.01.02 Balance Sheet Amounts in 000s

		Solvency II Value C0010
Assets	Baaaa	
ntangible assets Deferred tax assets	R0030 R0040	70,62
Pension benefit surplus	R0050	70,02
Property, plant & equipment held for own use	R0060	105,62
nvestments (other than assets held for index-linked and unit-linked contracts)	R0070	5,915,176
Property (other than for own use)	R0080	413,58
loldings in related undertakings, including participations	R0090	1,228,493
Equities	R0100	9,759
- Equities - Listed	R0110	0.75
- Equities - Unlisted	R0120	2,295,356
- Government Bonds	R0130 R0140	1,294,26
- Corporate Bonds	R0150	1,001,09
- Structured Notes	R0160	.,
- Collateralised securities	R0170	
Collective Investments Undertakings	R0180	1,775,964
Derivatives	R0190	150,24
Deposits other than cash equivalents	R0200	41,77
Other investments	R0210	
Assets held for index-linked and unit-linked contracts	R0220	
.oans & mortgages	R0230	1,796,83
- Loans on policies	R0240	
- Loans & mortgages to individuals	R0250	1,796,830
- Other loans & mortgages Reinsurance recoverables from:	R0260 R0270	4,342,823
 Reinsurance recoverables from: Reinsurance recoverables - Non-life and health similiar to non-life 	R0270 R0280	3,731,152
Reinsurance recoverables - Non-life and nealth similar to non-life Reinsurance recoverables - Non-life excluding health	R0280 R0290	3,598,69
- Reinsurance recoverables - Health similar to non-life	R0300	132,45
- Reinsurance recoverables - Life and health similar to life, excluding health and index-linked and unit-linked	R0310	611,67
- Reinsurance recoverables - Health similar to life	R0320	
- Reinsurance recoverables - Life excluding health and index-linked and unit-linked	R0330	611,67
- Reinsurance recoverables - Life index-linked and unit-linked	R0340	
Deposits to cedants	R0350	
nsurance & intermediaries receivables	R0360	3,27
Reinsurance receivables	R0370	23,64
Receivables (trade, not insurance)	R0380	409,519
Own Shares (held directly)	R0390	
Amounts due in respect of own fund items or initial fund called up but not yet paid in	R0400	
Cash and cash equivalents	R0410	95,60
Any other assets, not elsewhere shown Total assets	R0420 R0500	57,13
	HUSUU	12,020,20
Liabilities Technical provisions - Non-life	R0510	5,453,23
- Technical provisions - Non-life (excluding health)	R0520	5,361,214
- TP calculated as a whole - Non-life (excluding health)	R0530	-,,
- Best Estimate - Non-life (excluding health)	R0540	5,176,42
- Risk margin - Non-life (excluding health)	R0550	184,78
		92,02
- Technical provisions - Health (similar to non-life)	R0560	
- Technical provisions - Health (similar to non-life) - TP calculated as a whole - Health (similar to non-life)	R0560 R0570	
		88,57
- TP calculated as a whole - Health (similar to non-life)	R0570	
- TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life)	R0570 R0580	3,44
- TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life)	R0570 R0580 R0590	3,44
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Fechnical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) 	R0570 R0580 R0590 R0600 R0610 R0620	88,57 3,44 740,76
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Fechnical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) 	R0570 R0580 R0590 R0600 R0610 R0620 R0630	3,44
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Fechnical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) 	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640	3,44 740,76
- TP calculated as a whole - Health (similar to non-life) - Best Estimate - Health (similar to non-life) - Risk margin - Health (similar to non-life) Fechnical provisions - Life (excluding index-linked and unit linked) - Technical provisions - Health (similar to life) - TP calculated as a whole - Health (similar to life) - Best Estimate - Health (similar to life) - Best Estimate - Health (similar to life) - Risk margin - Health (similar to life) - Risk margin - Health (similar to life) - Technical provisions - Life (excluding health and index-linked and unit-linked)	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0630 R0640 R0650	3,44 740,76
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Fechnical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) 	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660	3,44 740,76 740,76
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Fechnical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) 	R0570 R0580 R0590 R0600 R0610 R0630 R0630 R0640 R0650 R0660 R0670	3,44 740,76 740,76 691,77
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Risk margin - Life (excluding index-linked and unit linked) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Te calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) 	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0670 R0680	3,44 740,76 740,76 691,77
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Risk margin - Life (excluding index-linked and unit-linked) Technical provisions - Life (excluding index-linked and unit-linked) Technical provisions - Health (similar to life) Te calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) 	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0660 R0660 R0680 R0680	3,44 740,76 740,76 691,77
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Technical provisions - Index-linked and unit-linked TP calculated as a whole - Index-linked and unit-linked 	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0660 R0680 R0680 R0690 R0700	3,44 740,76 740,76 691,77
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Risk margin - Life (excluding index-linked and unit-linked) Technical provisions - Life (excluding index-linked and unit-linked) Technical provisions - Health (similar to life) Te calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) 	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0660 R0660 R0680 R0680	3,44 740,76 740,76 691,77
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Best Estimate - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Index-linked and unit-linked Best Estimate - Index-linked and unit-linked Best Estimate - Index-linked and unit-linked 	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0670 R0680 R0680 R0680 R0690 R0700 R0710	3,44 740,76 740,76 691,77
TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Best Estimate - Index-linked and unit-linked Risk margin - Index-linked and unit-linked Best Estimate - Index-linked and unit-linked Risk margin - Index-linked and unit-linked Risk margin - Index-linked and unit-linked	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0700 R0710 R0720	3,44 740,76 740,76 691,77 48,98
TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Risk margin - Life (excluding index-linked and unit linked) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Rest Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Life (excluding health and index-linked and unit-linked) Risk margin - Life (excluding health and index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Index-linked and unit-linked Risk margin - Index-linked	R0570 R0580 R0590 R0600 R0610 R0630 R0630 R0640 R0650 R0660 R0670 R0680 R0700 R0710 R0720 R0720 R0740	3,44 740,76 740,76 691,77 48,98
TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) Technical provisions - Life (excluding health and index-linked and unit-linked) Technical provisions - Life (excluding health and index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Index-linked and unit-linked TP calculated as a whole - Index-linked and unit-linked Risk margin - Index-linked and unit-l	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0680 R0690 R0700 R0710 R0720 R0740 R0750 R0760 R0750 R0760	3,44 740,76 740,76 691,77 48,98 4,53 3,079,51
TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Index-linked and unit-linked TP calculated as a whole - Index-linked and unit-linked Risk margin - Index-linked and unit-linked Risk margin - Index-linked and unit-linked Dontingent liabilities Provisions other than technical provisions Peposits from reinsurers Deferred tax liabilities	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0660 R0660 R0660 R0670 R0680 R0700 R0710 R0720 R0740 R0750 R0760 R0770 R0770 R0780	3,44 740,76 691,77 48,98 4,53 3,079,511 16,65
TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) Technical provisions - Life (excluding health and index-linked and unit-linked) Technical provisions - Life (excluding health and index-linked and unit-linked) Te calculated as a whole - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Index-linked and unit-linked TP calculated as a whole - Index-linked and unit-linked Risk margin - Index-l	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0670 R0680 R0690 R0700 R0710 R0720 R0740 R0750 R0760 R0770 R0780 R0780 R0790	3,44 740,76 691,77 48,98 4,53 3,079,51 16,65 207,56
TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Technical provisions - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked Best Estimate - Life (excl health, index-linked and unit-linked Best Estimate - Life (excl health, index-linked and unit-linked Best Estimate - Life (excl health, index-linked and unit-linked Best Estimate - Life (excl health, index-linked and unit-linked Best Estimate - Life (excl health, i	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0690 R0700 R0700 R0720 R0740 R0750 R0760 R0760 R0760 R0780 R0790 R0790 R0800	3,44 740,76 691,77 48,98 4,53 3,079,51 16,65 207,56 312,71
TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Technical provisions - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Index-linked and unit-linked TP calculated as a whole - Index-linked and unit-linked Best Estimate - Index-linked and unit-linked	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0670 R0680 R0700 R0700 R0710 R0720 R0740 R0750 R0760 R0770 R0760 R0770 R0780 R0790 R0800 R0810	3,44 740,76 691,77 48,98 4,53 3,079,51 16,65 207,56 312,71 40,39
TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Best Estimate - Life (excluding health and index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Index-linked and unit-linked Risk margin - Index-linked and unit-linked Best Estimate - Index-linked and unit-linked Risk margin - Index-linked and unit-li	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0660 R0660 R0670 R0680 R0700 R0710 R0720 R0740 R0750 R0760 R0770 R0780 R0800 R0810 R0810	3,44 740,76 691,77 48,98 4,53 3,079,51 16,65 207,56 312,71 40,39 81,09
TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Life (excluding health and index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked Risk margin - Index-linked and unit-linked Best Estimate - Index-linked and unit-linked Best Estimate - Index-linked and unit-linked Best Istimate - Index-linked Istimute Best Istimate - Index-Inked Istimute Best Istimate Best Istimate - In	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0680 R0690 R0700 R0710 R0720 R0740 R0750 R0760 R0760 R0780 R0790 R0800 R0810 R0820 R0830	3,44 740,76 691,77 48,98 4,53 3,079,51 16,65 207,56 312,71 40,39 81,09 50,57
TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Risk margin - Health (similar to life) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Index-linked and unit-linked Risk margin - Index-link	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0660 R0660 R0660 R0660 R0680 R0700 R0710 R0720 R0740 R0750 R0760 R0780 R0790 R0800 R0800 R0810 R0820 R0830 R0830	3,44 740,76 691,77 48,98 4,53 3,079,51 16,65 207,56 312,71 40,39 81,09 50,57 416,82
TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Te calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Index-linked and unit-linked Detrosions other than technical provisions Porovisions other than technical provisions Porovisions ther than technical provisions Porovisions the tran technical provisions Porovisions to the than debts owed to credit institutions Insurance & intermediaries payables Reinsurance & intermediaries payables Payables (trade, not insurance) Subordinated liabilities	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0700 R0700 R0700 R0720 R0740 R0750 R0760 R0760 R0780 R0780 R0800 R0810 R0820 R0830 R0830 R0840 R0850	3,44
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Frechnical provisions - Life (excluding index-linked and unit linked) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Index-linked and unit-linked Provisions - Index-linked and unit-linked Best Estimate - Index-linked and unit-linked Risk margin - Index-linked and unit-linked Provisions other than technical provisions Paresion benefit obligations Deposits from reinsurers Deferred tax liabilities Detots owed to credit institutions Inancial liabilities other than debts owed to credit institutions Inancial liabilities other than debts owed to credit institutions Inancial liabilities other than debts owed to credit institutions Inancial liabilities other than debts owed to credit institutions Inancial liabilities other than debts owed to credit institutions Inancial li	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0700 R0700 R0700 R0700 R0700 R0700 R0700 R0700 R0760 R0760 R0770 R0760 R0770 R0780 R0800 R0800 R0810 R0820 R0830 R0830 R0840 R0850 R0860	3,44 740,76 691,77 48,98 4,53 3,079,51 16,65 207,56 312,71 40,39 81,09 50,57 416,82 279,41
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) TP calculated as a whole - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Index-linked and unit-linked Best Estimate - Index-linked and unit-linked Risk margin - Index-linked and unit-linked Provisions other than technical provisions Payotist from reinsurers Deferred tax liabilities Derivatives Detivatives Detivatives Detivatives Detivatives Payables (trade, not insurance) Subordinated liabilities not in BOF Subordinated liabilities not in BOF	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0630 R0640 R0630 R0640 R0650 R0660 R0670 R0680 R0700 R0710 R0720 R0760 R0770 R0780 R0790 R0800 R0810 R0820 R0830 R0830 R0830 R0840 R0850 R0850 R0850	3,44 740,76 740,76 691,77 48,98 4,53 3,079,51 16,65 207,56 312,71 40,39 81,09 50,57 416,82 279,41 279,41
 TP calculated as a whole - Health (similar to non-life) Best Estimate - Health (similar to non-life) Risk margin - Health (similar to non-life) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Life (excluding index-linked and unit linked) Technical provisions - Health (similar to life) Best Estimate - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Risk margin - Health (similar to life) Technical provisions - Life (excluding health and index-linked and unit-linked) TP calculated as a whole - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Best Estimate - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Life (excl health, index-linked and unit-linked) Risk margin - Index-linked and unit-linked TP calculated as a whole - Index-linked and unit-linked Risk margin - Index-linked and unit-linked Provisions other than technical provisions Paresion benefit obligations Deposits from reinsurers Deferred tax liabilities Derivatives Debts owed to credit institutions Inancial liabilities other than debts owed to credit institutions Inancial liabilities other than debts owed to credit institutions Inancial liabilities other than debts owed to credit institutions Inancial liabilities (trade, not insurance) Subordinated liabilities Subordinated liabilities ot in	R0570 R0580 R0590 R0600 R0610 R0620 R0630 R0640 R0650 R0660 R0670 R0680 R0700 R0700 R0700 R0700 R0700 R0700 R0700 R0700 R0760 R0760 R0770 R0760 R0770 R0780 R0800 R0800 R0810 R0820 R0830 R0830 R0840 R0850 R0860	3,44 740,76 691,77 48,98 4,53 3,079,51 16,65 207,56 312,71 40,39 81,09 50,57 416,82 279,41

Appendix F.1.2.1 S.05.01.02

Premiums, claims and expenses by line of business Amounts in 000s

Amounts in 000s

			L	ine of Business for: li	fe insurance obligation	S		Life reinsuran		
		Health [accepted non-proportional reinsurance]	Insurance with profit participation	Unit-linked or index-linked insurance	Other life insurance	Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance	Health reinsurance	Life reinsurance	Total
		C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0300
Premiums written										
Gross - Direct Business	R1410									
Reinsurers' share	R1420									
Net	R1500									
Premiums earned										
Gross - Direct Business	R1510									
Reinsurers' share	R1520									
Net	R1600									
Claims incurred										
Gross - Direct Business	R1610						91,128			91,128
Reinsurers' share	R1620						81,331			81,331
Net	R1700						9,797			9,797
Changes in other technical provisions										
Gross - Direct Business	R1710									
Reinsurers' share	R1720									
Net	R1800									
Expenses incurred	R1900									
Other expenses	R2500									
Total expenses	R2600									

Appendix F.1.2.2 S.05.01.02

S.05.01.02 Premiums, claims and expenses by line of business

Amounts in 000s

					Line of Business	for: non-life insurance	e and reinsurance oblig	ations (direct business	and accepted proportion	onal reinsurance)			
		Medical expense insurance [direct business]	Income protection insurance [direct business]	Workers' compensation insurance [direct business]	Motor vehicle liability insurance [direct business]	Other motor insurance [direct business]	Marine, aviation and transport insurance [direct business]	Fire and other damage to property insurance [direct business]	General liability insurance [direct business]	Credit and suretyship insurance [direct business]	Legal expenses insurance [direct business]	Assistance [direct business]	Miscellaneous financial loss [direc business]
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120
Premiums written													
Gross - Direct Business	R0110	574,083	70,529		1,340,823	335,206	46,183	1,934,178	485,225	36,081		53,552	43,625
Gross - Proportional reinsurance accepted	R0120		1,127		501,712	125,428	10,377	381,299	331,067	2,715			3,153
Gross - Non-proportional reinsurance accepted	R0130												
Reinsurers' share	R0140	287,042	36,441		961,143	240,286	29,359	1,275,245	309,778	26,088		26,776	27,119
Net	R0200	287,042	35,215		881,393	220,348	27,201	1,040,232	506,515	12,708		26,776	19,659
Premiums earned													
Gross - Direct Business	R0210	572,245	69,244		1,359,392	339,848	42,715	1,876,215	457,469	29,975		53,605	42,510
Gross - Proportional reinsurance accepted	R0220		738		422,950	105,737	10,340	311,168	297,508	1,682			299
Gross - Non-proportional reinsurance accepted	R0230												
Reinsurers' share	R0240	286,123	35,686		986,659	246,665	27,738	1,241,230	292,891	20,064		26,802	22,668
Net	R0300	286,123	34,297		795,684	198,921	25,318	946,153	462,086	11,593		26,802	20,142
Claims incurred													
Gross - Direct Business	R0310	406,598	33,985		989,638	247,410	41,835	824,414	354,885	14,774		40,425	19,602
Gross - Proportional reinsurance accepted	R0320		108		354,850	88,713	6,388	159,348	270,379	750			48
Gross - Non-proportional reinsurance accepted	R0330												
Reinsurers' share	R0340	194,087	16,917		756,726	189,182	28,842	499,584	254,679	10,183		20,213	9,830
Net	R0400	212,511	17,177		587,762	146,941	19,381	484,177	370,584	5,340		20,213	9,819
Changes in other technical provisions													
Gross - Direct Business	R0410		505										505
Gross - Proportional reinsurance accepted	R0420												
Gross - Non-proportional reinsurance accepted	R0430												
Reinsurers' share	R0440		-252										-252
Net	R0500		757										757
Expenses incurred	R0550	60,589	14,639		192,800	48,200	8,840	478,904	95,175	4,625		7,728	11,605
Other expenses	R1200												
Total expenses	R1300												

		Line of	Business for: accepte	ed non proportional reins	surance	
		Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport reinsurance	Non-proportional property reinsurance	Total
		C0130	C0140	C0150	C0160	C0200
Premiums written						
Gross - Direct Business	R0110					4,919,486
Gross - Proportional reinsurance accepted	R0120					1,356,878
Gross - Non-proportional reinsurance accepted	R0130					
Reinsurers' share	R0140					3,219,275
Net	R0200					3,057,089
Premiums earned						
Gross - Direct Business	R0210					4,843,220
Gross - Proportional reinsurance accepted	R0220					1,150,422
Gross - Non-proportional reinsurance accepted	R0230					
Reinsurers' share	R0240					3,186,524
Net	R0300					2,807,118
Claims incurred						
Gross - Direct Business	R0310					2,973,567
Gross - Proportional reinsurance accepted	R0320					880,583
Gross - Non-proportional reinsurance accepted	R0330					
Reinsurers' share	R0340					1,980,244
Net	R0400					1,873,905
Changes in other technical provisions						
Gross - Direct Business	R0410					1,010
Gross - Proportional reinsurance accepted	R0420					
Gross - Non-proportional reinsurance accepted	R0430					
Reinsurers' share	R0440					-505
Net	R0500					1,514
Expenses incurred	R0550					923.106
Other expenses	R1200					26,150
Total expenses	R1300					949,256

Appendix F.1.2.3 S.05.02.01 Premiums, claims and expenses by Country Amounts in 000s

		Home Country		Total Top 5 and home country				
		C0150	C0160	C0170	C0180	C0190	C0200	C0210
	R1400							
		C0220	C0230	C0240	C0250	C0260	C0270	C0280
Premiums written								
Gross	R1410							
Reinsurers' share	R1420							
Net	R1500							
Premiums earned								
Gross	R1510							
Reinsurers' share	R1520							
Net	R1600							
Claims incurred								
Gross	R1610	91,128						91,128
Reinsurers' share	R1620	81,331						81,331
Net	R1700	9,797						9,797
Changes in other technical provisions								
Gross	R1710							
Reinsurers' share	R1720							
Net	R1800							
Expenses incurred	R1900							
Other expenses	R2500							
Total expenses	R2600							

Appendix F.1.2.4 S.05.02.01 Premiums, claims and expenses by Country Amounts in 000s

		Home Country	Тор	5 countries (by amoun	t of gross premium writt	ten) - non-life obligation	s	Total Top 5 and home country
		C0010	C0020	C0030	C0040	C0050	C0060	C0070
	R0010		IE	US	ES	NL	DE	
		C0080	C0090	C0100	C0110	C0120	C0130	C0080
Premiums written								
Gross - Direct Business	R0110	4,845,185	41,579	24,288	2,872	589	339	4,914,853
Gross - Proportional reinsurance accepted	R0120	198,189	1,158,689					1,356,878
Gross - Non-proportional reinsurance accepted	R0130							
Reinsurers' share	R0140	2,731,706	466,206	16,574	1,441	308	198	3,216,433
Net	R0200	2,311,668	734,063	7,714	1,430	281	141	3,055,298
Premiums earned								
Gross - Direct Business	R0210	4,774,904	41,191	18,561	2,882	574	304	4,838,417
Gross - Proportional reinsurance accepted	R0220	198,469	951,953					1,150,422
Gross - Non-proportional reinsurance accepted	R0230							
Reinsurers' share	R0240	2,687,794	481,768	12,666	1,437	299	176	3,184,139
Net	R0300	2,285,579	511,376	5,895	1,446	275	129	2,804,700
Claims incurred								
Gross - Direct Business	R0310	2,905,254	26,388	15,172	1,246	768	230	2,949,058
Gross - Proportional reinsurance accepted	R0320	69,674	810,908					880,583
Gross - Non-proportional reinsurance accepted	R0330							
Reinsurers' share	R0340	1,549,713	403,933	9,861	622	393	132	1,964,654
Net	R0400	1,425,215	433,363	5,311	624	374	99	1,864,987
Changes in other technical provisions								
Gross - Direct Business	R0410	1,010						1,010
Gross - Proportional reinsurance accepted	R0420							
Gross - Non-proportional reinsurance accepted	R0430							
Reinsurers' share	R0440	-505						-505
Net	R0500	1,514						1,514
Expenses incurred	R0550	858,344	59,313	3,033	571	228	55	921,545
Other expenses	R1200							26,150
Total expenses	R1300							947,695

Appendix F.1.3.1 S.12.01.02 Life and Health SLT Technical Provisions Amounts in 000s

	1	Insurance with profit participation		Unit-linked or index-linked insurance			Other life insurance		Annuities stemming from non-life insurance contracts and relating to insurance obligations other than bealth insurance	Accepted reinsurance	
					Contracts without options and guarantees	Contracts with options or quarantees		Contracts without options and guarantees	Contracts with options or quarantees		
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0150
Technical provisions calculated as a whole	R0010										
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0020										
Technical provisions calculated as a sum of BE and RM Best Estimate											
Gross Best Estimate	R0030								691,620	155	691,775
Total Recoverables from reinsurance and SPV after the adjustment for expected losses due to counterparty default	R0080								611,671		611,671
Best estimate minus recoverables from reinsurance and SPV - Total	R0090								79,948	155	80,104
Risk Margin	R0100								48,932	52	48,985
Amount of the transitional on Technical Provisions											
Technical Provisions calculated as a whole	R0110										
Best estimate	R0120										
Risk margin	R0130										
Technical provisions - Total	R0200								740,552	208	740,760

		Health [accepted non-proportional reinsurance]			Annuities stemming from non-life insurance contracts and relating to bealth insurance obli	Health reinsurance	
			Contracts without options and guarantees	Contracts with options or quarantees			Total (Health similar to life insurance)
		C0160	C0170	C0180	C0190	C0200	C0210
Technical provisions calculated as a whole	R0010						
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0020						
Technical provisions calculated as a sum of BE and RM							
Best Estimate							
Gross Best Estimate	R0030						
Total Recoverables from reinsurance and SPV after the adjustment for expected losses due to counterparty default	R0080						
Best estimate minus recoverables from reinsurance and SPV - Total	R0090						
Risk Margin	R0100						
Amount of the transitional on Technical Provisions							
Technical Provisions calculated as a whole	R0110						
Best estimate	R0120						
Risk margin	R0130						
Technical provisions - Total	R0200						

Appendix F.1.3.2 S.17.01.02

S.17.01.02 Non-Life Technical Provisions

Amounts in 000s

						Direct business	and accepted	proportional	reinsurance				
		Medical expense insurance [direct business]	Income protection insurance [direct business]	Workers' compensation insurance [direct business]	Motor vehicle liability insurance [direct business]	Other motor insurance [direct business]	Marine, aviation and transport insurance [direct business]	Fire and other damage to property insurance [direct business]	General liability insurance [direct business]	Credit and suretyship insurance [direct business]	Legal expenses insurance [direct business]	Assistance [direct business]	Miscellaneous financial loss [direct business]
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130
Technical provisions calculated as a whole	R0010												
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0050												
Technical provisions calculated as a sum of BE and RM													
Best estimate													
Premium provisions													
Gross	R0060	18,406	-205		233,590	108,587	5,006	40,373	36,652	-137		9,590	549
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0140	88,026	7,566		228,127	113,377	5,563	294,228	69,752	4,178		4,123	4,237
Net Best Estimate of Premium Provisions	R0150	-69,620	-7,771		5,463	-4,790	-558	-253,855	-33,100	-4,315		5,467	-3,688
Claims provisions													
Gross	R0160	48,404	21,971		2,044,419	54,530	51,704	635,481	1,895,247	14,607		21,859	23,530
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0240	24,203	12,661		1,023,112	32,727	33,614	392,957	1,359,914	8,909		11,335	12,124
Net Best Estimate of Claims Provisions	R0250	24,202	9,310		1,021,308	21,803	18,090	242,524	535,334	5,698		10,523	11,406
Total Best estimate - Gross	R0260	66,810	21,766		2,278,010	163,117	56,709	675,854	1,931,900	14,470		31,449	24,078
Total Best estimate - Net	R0270	-45,418	1,539		1,026,771	17,013	17,532	-11,331	502,234	1,383		15,991	7,718
Risk margin	R0280	3,160	285		76,873	4,286	392	17,205	85,401	189		234	175
Amount of the transitional on Technical Provisions													
Technical Provisions calculated as a whole	R0290												
Best estimate	R0300												
Risk margin	R0310												
Technical provisions - Total													
Technical provisions - Total	R0320	69,970	22,051		2,354,882	167,403	57,101	693,059	2,017,300	14,660		31,683	24,253
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses due to counterparty default - Total	R0330	112,229	20,227		1,251,239	146,104	39,177	687,185	1,429,666	13,088		15,458	16,361
Technical provisions minus recoverables from reinsurance/SPV and Finite Re - Tota	R0340	-42,258	1,824		1,103,644	21,298	17,924	5,874	587,634	1,572		16,225	7,893

		Accepted	non-proportional	reinsurance		
		Health [accepted non-proportional reinsurance]	Casualty [accepted non-proportional reinsurance]	Marine, aviation, transport [accepted non-proportional reinsurance] Property [accept non-proportion reinsurance]		Total Non-Life obligation
		C0140	C0150	C0160	C0170	C0180
Technical provisions calculated as a whole	R0010					
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0050					
Fechnical provisions calculated as a sum of BE and RM						
Best estimate						
Premium provisions						
Gross	R0060					452,411
otal recoverable from reinsurance/SPV and Finite Re after the adjustment for xpected losses due to counterparty default	R0140					819,177
let Best Estimate of Premium Provisions	R0150					-366,766
Claims provisions						
aross	R0160		836	2		4,812,591
otal recoverable from reinsurance/SPV and Finite Re after the adjustment for xpected losses due to counterparty default	R0240		418	1		2,911,975
let Best Estimate of Claims Provisions	R0250		418	1		1,900,616
otal Best estimate - Gross	R0260		836	2		5,265,002
fotal Best estimate - Net	R0270		418	1		1,533,850
Risk margin	R0280		35	0		188,234
Amount of the transitional on Technical Provisions						
echnical Provisions calculated as a whole	R0290					
Best estimate	R0300					
Risk margin	R0310					
Fechnical provisions - Total						
echnical provisions - Total	R0320		871	2		5,453,235
tecoverable from reinsurance contract/SPV and Finite Re after the adjustment for xpected losses due to counterparty default - Total	R0330		418	1		3,731,152
Fechnical provisions minus recoverables from reinsurance/SPV and Finite Re - Total	R0340		453	1		1,722,083

Appendix F.1.4 S.19.01.21

Non-Life Insurance Claims Information

Amounts in 000s

Total Non-Life Business

Accident year / Underwriting year **Z0020** AY

Gross Claims Paid (non-cumulative)

(absolute amount)

						Development Y	ear							In Current year	Sum of years (cumulative)
		0	1	2	3	4	5	6	7	8	9	10&+			
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110		C0170	C0180
Prior	R0100											87,636	R0100	87,636	15,996,406
R0160	R0160	1,005,421	775,720	215,164	150,658	95,779	60,138	28,259	-2,315	2,723	4,488		R0160	4,488	2,336,034
R0170	R0170	967,757	604,088	215,261	140,678	127,213	62,101	32,011	24,032	21,955			R0170	21,955	2,195,097
R0180	R0180	1,035,274	624,488	228,132	160,778	124,806	88,790	38,766	30,997				R0180	30,997	2,332,032
R0190	R0190	990,716	562,444	200,870	137,147	126,061	105,942	49,468					R0190	49,468	2,172,648
R0200	R0200	994,373	539,122	192,753	136,634	158,676	98,165						R0200	98,165	2,119,722
R0210	R0210	1,040,356	653,996	253,155	158,216	116,433							R0210	116,433	2,222,156
R0220	R0220	1,138,083	617,332	207,454	160,614								R0220	160,614	2,123,483
R0230	R0230	1,208,379	566,493	209,279									R0230	209,279	1,984,151
R0240	R0240	1,338,122	623,375										R0240	623,375	1,961,498
R0250	R0250	1,358,835											R0250	1,358,835	1,358,835
												То	tal R0260	2,761,245	36,802,061

Gross undiscounted Best Estimate Claims Provisions

(absolute amount)

(ausoure amount)					Development	/ear							Year end (discounted data)
	0	1	2	3	4	5	6	7	8	9	10&+		()
	C0200	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0290	C0300		C0360
Prior R010	0										1,100,167	R0100	971,644
R0160 R016	0						50,192	39,317	30,075	28,390		R0160	27,716
R0170 R017	0					110,830	80,222	39,263	36,573			R0170	35,751
R0180 R018	0				273,392	151,545	85,037	58,803				R0180	57,595
R0190 R015	0			397,740	236,738	106,328	71,584					R0190	70,585
R0200 R020	0		544,217	395,035	208,937	123,740						R0200	121,747
R0210 R02	0	852,070	547,723	318,186	253,016							R0210	249,565
R0220 R022	0 1,347,669	807,754	522,664	441,285								R0220	435,526
R0230 R023	0 1,211,001	639,866	562,581									R0230	554,883
R0240 R024	0 1,200,763	836,950										R0240	823,485
R0250 R025	0 1,437,185											R0250	1,415,725
											т	otal R0260	4,764,221

Appendix F.1.5 S.22.01.21 Impact of long term guarantees and transitional measures Amounts in 000s

		Amount with LG measures and transitionals	Impact of transitional on technical provisions	Impact of transitional on interest rate	Impact of volatility adjustment set to zero	Impact of matching adjustment set to zero
		C0010	C0030	C0050	C0070	C0090
Technical Provisions	R0010	6,193,995			57,781	
Basic Own Funds	R0020	2,139,641			-11,739	
Eligible own funds to meet Solvency Capital Requirement	R0050	2,139,641	0		-11,739	0
Solvency Capital Requirement	R0090	1,147,940			23,236	
Eligible own funds to meet Minimum Capital Requirement	R0100	1,872,887	0		-11,590	0
Minimum Capital Requirement	R0110	416,418			743	

Amounts in 000s						
		Total	Tier 1 Unrestricted	Tier 1 Restricted	Tier 2	Tier 3
Dasia anya funda kafaya daduatian fay matisinatiana in atkay financial asatay		C0010	C0020	C0030	C0040	C0050
Basic own funds before deduction for participations in other financial sector is foreseen in article 68 of Delegated Regulation 2015/35						
Ordinary share capital (gross of own shares)	R0010	203,640	203,640			
hare premium account related to ordinary share capital	R0030					
nitial funds, members' contributions or the equivalent basic own fund item for nutual and mutual-type undertakings	R0040					
ubordinated mutual member accounts	R0050					
urplus funds	R0070					
reference shares	R0090					
hare premium account related to preference shares	R0110					
Reconciliation reserve	R0130	1,585,964	1,585,964			
Subordinated liabilities	R0140	279,411			279,411	
in amount equal to the value of net deferred tax assets	R0160	70,627				70,62
ther own fund items approved by the supervisory authority as basic own funds no		10,021				70,02
pecified above wn funds from the financial statements that should not be represented by he reconciliation reserve and do not meet the criteria to be classified as olvency II own funds wn funds from the financial statements that should not be represented by the econciliation reserve and do not meet the criteria to be classified as Solvency II ow unds						
eductions						
eductions for participations in financial and credit institutions	R0230					
otal basic own funds after deductions	R0290	2,139,641	1,789,604		279,411	70,62
ncillary own funds						
npaid and uncalled ordinary share capital callable on demand	R0300					
npaid and uncalled initial funds, members' contributions or the equivalent basic vn fund item for mutual and mutual-type undertakings, callable on demand	R0310					
npaid and uncalled preference shares callable on demand	R0320					
legally binding commitment to subscribe and pay for subordinated liabilities on emand	R0330					
etters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC	R0340					
etters of credit and guarantees other than under Article 96(2) of the Directive 009/138/EC	R0350					
upplementary members calls under first subparagraph of Article 96(3) of the irective 2009/138/EC	R0360					
upplementary members calls other than under first subparagraph of Article 96(3) the Directive 2009/138/EC	R0370					
ther ancillary own funds	R0390					
otal ancillary own funds - Solo	R0400					
vailable and eligible own funds						
otal available own funds to meet the SCR	R0500	2,139,641	1,789,604		279,411	70,6
otal available own funds to meet the MCR	R0510	2,069,015	1,789,604		279,411	
otal eligible own funds to meet the SCR	R0540	2,139,641	1,789,604		279,411	70,6
otal eligible own funds to meet the MCR	R0550	1,872,887	1,789,604		83,284	
CR	R0580	1,147,940				
CR	R0600	416,418				
atio of eligible own funds to SCR	R0620	1.8639				
atio of eligible own funds to MCR	R0640	4.4976				
·····		C0060				
econciliation Reserve						
xcess of assets over liabilities	R0700	1,860,231				
wn shares (held directly and indirectly)	R0710					
oreseeable dividends, distributions and charges	R0720					
ther basic own fund items	R0730	274,267				
djustment for restricted own fund items in respect of matching adjustment ortfolios and ring fenced funds	R0740					
leconciliation reserve xpected profits	R0760	1,585,964			`	
	D.0770					

Expected profits included in future premiums ($\ensuremath{\mathsf{EPIFP}}\xspace)$ - Life business

Expected profits included in future premiums (EPIFP) - Non-life business	

Total expected profits included in future premiums (EPIFP)

19,024

19,024

R0770 R0780

R0790

Appendix F.1.7 S.25.02.21 Solvency Capital Requirement - For undertakings using the standard formula and partial internal mode Amounts in 000s

nique number o component	f Component Description		Calculation of the Solvency Capital Requirement	Amount modelled	USP	Simplifications	LAC DT
C0010	C0020		C0030	C0070	C0090	C0120	C0130
0000	Market Risk		768,453	718,058		None	
0000	Counterparty Risk		101,063	90,545			
0000	Life underwriting risk				None	None	
0000	Health underwriting risk		39,680		None	None	
0000	Non-life underwriting risk		685,651	685,651	None	None	
1000	Operational risk		358,185	343,209			
1000	Other risks						
2000	Loss-absorbing capacity of technical provisions						
3000	Loss-absorbing capacity of deferred tax		-74,444	-74,444			
4000	Other adjustments		16,249	16,249			
	Calculation of Solvency Capital Requirement		C0100				
	Total undiversified components	R0110	1,894,837				
	Diversification	R0060	-746,897				
	Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	R0160					
	Solvency Capital Requirement excluding capital add-on	R0200	1,147,940				
	Capital add-ons already set	R0210					
	Solvency capital requirement	R0220	1,147,940				
	Other information on SCR						
	Amount/Estimate of the overall loss-absorbing capacity of technical provisions	R0300					
	Amount/Estimate of the overall loss-absorbing capacity of deferred taxes	R0310	-74,444				
	Capital requirement for duration-based equity risk sub-module	R0400					
	Total amount of Notional Solvency Capital Requirements for remaining part	R0410	1,148,506				
	Total amount of Notional Solvency Capital Requirements for ring fenced funds	R0420					
	Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	R0430					
	Diversification effects due to RFF nSCR aggregation for article 304	R0440					
			Approach based on average tax rate				
	Approach to tax rate		C0109				
CRB2B-305	Approach based on average tax rate	R0590	2				
	Calculation of loss absorbing capacity of deferred taxes					-	
CRB2B-4T2	LAC DT	R0640					-74
CRB2B-420	LAC DT justified by reversion of deferred tax liabilities	R0650					-1
CRB2B-425	LAC DT justified by reference to probable future taxable profit	R0660					-73
CRB2B-430	LAC DT justified by carry back, current year	R0670					
CRB2B-435	LAC DT justified by carry back, future years	R0680					
CRB2B-440	Maximum LAC DT	R0690					-219

Appendix F.1.8 S.28.01.01

Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity Amounts in 000s

Linear formula component for non-life insurance and reinsurance obligations

MCRNL Result	R0010	C0010 414,736			
				Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
				C0020	C0030
Medical expense insurance and proportional reinsurance			R0020		287,043
Income protection insurance and proportional reinsurance			R0030	1,539	35,215
Workers' compensation insurance and proportional reinsurance			R0040		
Motor vehicle liability insurance and proportional reinsurance			R0050	1,026,771	873,510
Other motor insurance and proportional reinsurance			R0060	17,013	218,378
Marine, aviation and transport insurance and proportional reinsurance			R0070	17,532	27,201
Fire and other damage to property insurance and proportional reinsurance			R0080		1,036,284
General liability insurance and proportional reinsurance			R0090	502,234	496,962
Credit and suretyship insurance and proportional reinsurance			R0100	1,383	12,708
Legal expenses insurance and proportional reinsurance			R0110		
Assistance and proportional reinsurance			R0120	15,991	26,776
Miscellaneous financial loss insurance and proportional reinsurance			R0130	7,718	19,659
Non-proportional health reinsurance			R0140		
Non-proportional casualty reinsurance			R0150	418	
Non-proportional marine, aviation and transport reinsurance			R0160	1	
Non-proportional property reinsurance			R0170		

Linear formula component for life insurance and reinsurance obligations

	Res	

Obligations with profit participation - Guaranteed benefits
Obligations with profit participation - Future discretionary benefits
Index-linked and unit-linked insurance obligations
Other life (re)insurance and health (re)insurance obligations
Total capital at risk for all life (re)insurance obligations

Overall MCR calculation

		C0070
Linear MCR	R0300	416,418
SCR	R0310	1,147,940
MCR cap	R0320	516,573
MCR floor	R0330	286,985
Combined MCR	R0340	416,418
Absolute floor of the MCR	R0350	3,187
		C0070

Minimum Capital Requirement

	C0070
R0300	416,418
R0310	1,147,940
R0320	516,573
R0330	286,985
R0340	416,418
R0350	3,187
	C0070
R0400	416,418

C0040 1,682

Net (of reinsurance/SPV) best estimate and TP calculated as a

whole C0050

80,104

R0210 R0220 R0230 R0240

R0250

Net (of reinsurance/SPV) total capital at risk

C0060

R0200

F.2 Glossary of Abbreviations and Definitions

A glossary explaining the key terms used in this report is available on www.aviva.com/glossary.

F.3 Directors' Statement

We acknowledge our responsibility for preparing the Solvency and Financial Condition Report of Aviva Insurance Limited at 31 December 2019 in all material respects in accordance with the PRA Rules and the Solvency II Regulations.

The Board is satisfied that to the best of its knowledge and belief:

(a) throughout the financial year to 31 December 2019, the Company has complied in all material respects with the requirements of the PRA rules and Solvency II Regulations as applicable to the Company; and

(b) it is reasonable to believe that in respect of the period from 31 December 2019 to the date of the publication of the SFCR, the Company has continued so to comply and that it will continue so to comply for the remainder of the financial year to 31 December 2020.

S Maillet Director 7 April 2020

F.4 Auditors Report

Report of the external independent auditors to the Directors of Aviva Insurance Limited ('the Company') pursuant to Rule 4.1 (2) of the External Audit Part of the PRA Rulebook applicable to Solvency II firms

Report on the Audit of the relevant elements of the Solvency and Financial Condition Report

Opinion

Except as stated below, we have audited the following documents prepared by the Company as at 31 December 2019:

- The 'Valuation for solvency purposes' and 'Capital Management' sections of the Solvency and Financial Condition Report of the Company as at 31 December 2019, ('**the Narrative Disclosures subject to audit**'); and
- Company templates S.02.01.02, S.12.01.02, S.17.01.02, S.22.01.21, S.23.01.01 and S.28.01.01 ('the Templates subject to audit').

The Narrative Disclosures subject to audit and the Templates subject to audit are collectively referred to as the 'relevant elements of the Solvency and Financial Condition Report'.

We are not required to audit, nor have we audited, and as a consequence do not express an opinion on the **Other Information** which comprises:

- Information contained within the relevant elements of the Solvency and Financial Condition Report set out above which is, or derives from the Solvency Capital Requirement, as identified in the Appendix to this report;
- The 'Summary', 'Business and performance', 'System of governance' and 'Risk profile' elements of the Solvency and Financial Condition Report;
- Company templates S.05.01.02, S.05.02.01, S.19.01.21 and S.25.02.21;
- The written acknowledgement by management of their responsibilities, including for the preparation of the Solvency and Financial Condition Report ('**Directors' Statement**').

To the extent the information subject to audit in the relevant elements of the Solvency and Financial Condition Report includes amounts that are totals, sub-totals or calculations derived from the Other Information, we have relied without verification on the Other Information.

In our opinion, the information subject to audit in the relevant elements of the Solvency and Financial Condition Report of the Company as at 31 December 2019 is prepared, in all material respects, in accordance with the financial reporting provisions of the PRA Rules and Solvency II regulations on which they are based, as supplemented by supervisory approvals.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) including ISA (UK) 800 and ISA (UK) 805, and applicable law. Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the relevant elements of the Solvency and Financial Condition Report* section of our report. We

are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the Solvency and Financial Condition Report in the UK, including the FRC's Ethical Standard as applied to public interest entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

ISAs (UK) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the Solvency and Financial Condition Report is not appropriate; or
- the directors have not disclosed in the Solvency and Financial Condition Report any identified material uncertainties that may cast significant doubt about the Company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the Solvency and Financial Condition Report is authorised for issue.

We have nothing to report in respect of the above matters.

However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the Company's ability to continue as a going concern.

Emphasis of Matter - Basis of Accounting

We draw attention to the 'Valuation for solvency purposes' and Capital Management sections of the Solvency and Financial Condition Report, which describe the basis of accounting. The Solvency and Financial Condition Report is prepared in compliance with the financial reporting provisions of the PRA Rules and Solvency II regulations, and therefore in accordance with a special purpose financial reporting framework. The Solvency and Financial Condition Report is required to be published, and intended users include but are not limited to the Prudential Regulation Authority. As a result, the Solvency and Financial Condition Report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Other Information

The Directors are responsible for the Other Information.

Our opinion on the relevant elements of the Solvency and Financial Condition Report does not cover the Other Information and we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the Solvency and Financial Condition Report, our responsibility is to read the Other Information and, in doing so, consider whether the Other Information is materially inconsistent with the relevant elements of the Solvency and Financial Condition Report, or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the relevant elements of the Solvency and Financial Condition Report or a material misstatement of the Other Information. If, based on the work we have performed, we conclude that there is a material misstatement of this Other Information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Directors for the Solvency and Financial Condition Report

The Directors are responsible for the preparation of the Solvency and Financial Condition Report in accordance with the financial reporting provisions of the PRA rules and Solvency II regulations which have been supplemented by the approvals made by the PRA under the PRA Rules and Solvency II regulations on which they are based, as detailed below:

- Approval to use the volatility adjustment in the calculation of technical provisions; and
- Approval to use a partial internal model and the approval of subsequent major changes thereto.

The Directors are also responsible for such internal control as they determine is necessary to enable the preparation of a Solvency and Financial Condition Report that is free from material misstatement, whether due to fraud or error.

Auditors' Responsibilities for the Audit of the relevant elements of the Solvency and Financial Condition Report

It is our responsibility to form an independent opinion as to whether the information subject to audit in the relevant elements of the Solvency and Financial Condition Report is prepared, in all material respects, in accordance with financial reporting provisions of the PRA Rules and Solvency II regulations on which they are based.

Our objectives are to obtain reasonable assurance about whether the relevant elements of the Solvency and Financial Condition Report are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but it is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the decision making or the judgement of the users taken on the basis of the Solvency and Financial Condition Report.

A further description of our responsibilities for the audit is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

This report, including the opinion, has been prepared for the Board of Directors of the Company in accordance with External Audit rule 2.1 of the Solvency II firms Sector of the PRA Rulebook and for no other purpose. We do not, in providing this report, accept or assume responsibility for any other purpose or to any other party save where expressly agreed by our prior consent in writing.

Other Matter

The Company has authority to calculate its Solvency Capital Requirement using a partial internal model ("the Model") approved by the Prudential Regulation Authority in accordance with the Solvency II Regulations. In forming our opinion (and in accordance with PRA Rules), we are not required to audit the inputs to, design of, operating effectiveness of and outputs from the Model, or whether the Model is being applied in accordance with the Company's application or approval order.

Report on Other Legal and Regulatory Requirements

In accordance with Rule 4.1 (3) of the External Audit Part of the PRA Rulebook for Solvency II firms we are also required to consider whether the Other Information is materially inconsistent with our knowledge obtained in the audit of the Company's statutory financial statements. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

PricewaterhouseCoopers LLP Chartered Accountants London 7 April 2020

Appendix – relevant elements of the Solvency and Financial Condition Report that are not subject to audit

The relevant elements of the Solvency and Financial Condition Report that are not subject to audit comprise:

- The following elements of template S.02.01.02:
 - Row R0550: Technical provisions non-life (excluding health) risk margin
 - Row R0590: Technical provisions health (similar to non-life) risk margin
 - Row R0640: Technical provisions health (similar to life) risk margin
 - Row R0680: Technical provisions life (excluding health and index-linked and unit-linked) - risk margin
 - Row R0720: Technical provisions Index-linked and unit-linked risk margin
- The following elements of template S.12.01.02
 - Row R0100: Technical provisions calculated as a sum of BE and RM Risk margin
- The following elements of template S.17.01.02
 - Row R0280: Technical provisions calculated as a sum of BE and RM Risk margin
- The following elements of template S.22.01.21
 - Row R0010 Technical provisions
 - Row R0090 Solvency Capital Requirement

 - The following elements of template S.23.01.01
 - Row R0580: SCR
 - Row R0740: Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds
- The following elements of Company template S.28.01.01
 - Row R0310: SCR
- Elements of the Narrative Disclosures subject to audit identified as 'unaudited'.

F.5 Additional information on the COVID-19 global pandemic (unaudited)

On 11 March 2020, the World Health Organization declared the outbreak of a strain of novel coronavirus disease, COVID-19, a global pandemic. Governments in affected areas have imposed a number of measures designed to contain the outbreak, including business closures, travel restrictions, stay at home orders and cancellations of gatherings and events. The spread of COVID-19 has resulted in an economic downturn in jurisdictions in which the Company operates and the global economy more widely, as well as causing increased volatility and declines in financial markets. If the pandemic is prolonged, or further diseases emerge that give rise to similar effects, the adverse impact on the global economy could be deepened and result in further declines in financial markets.

As an insurer the Company is impacted by the COVID-19 pandemic through its general insurance products as a result of disruption to travel and businesses insured by the Company. The Company is also keeping its pricing and strategy under review given changes in the risk profile of future new business and expected future investment returns. The Company's balance sheet exposure has been reviewed and actions are being taken to further reduce the sensitivity to economic shocks. At FY19 the Company had strong solvency levels and expects to continue to meet its capital requirements. Since the onset of the pandemic the Company has remained operational, with key activities such as cash payments and transaction processing being maintained, IT systems remaining operational, and employees including frontline customer facing staff being supported to ensure that that the Company is there to support its customers when they need it most. Notwithstanding the Company's strong capital and liquidity position and the operational and financial actions that are being taken, deterioration in the situation could have further adverse implications arising from the impacts on financial markets, insurance exposures and operations.

As the situation is rapidly evolving it is not practicable to quantify the potential financial impact of the outbreak on the Company at this stage. Figures presented in the SFCR and the associated Quantitative Reporting Templates (QRTs) have been prepared based on conditions and best estimate assumptions at 31 December 2019 and have therefore not been adjusted for any impacts of COVID-19 including any impacts on technical provisions.

The following summarises the impact of COVID-19 on the information contained within sections A to E of the SFCR where this is considered relevant.

Business and performance

Information presented in Section A of this report represents the performance of the business as reported in the Company's financial statements for the 12-month period to 31 December 2019. As referred to above it is not practicable to quantify the potential financial impact of the outbreak on the company at this stage.

System of governance

The Company's overarching risk management and internal control system is responding well to the challenges of the COVID-19 outbreak and remains intact. Work is in progress to capture changes to the control environment to make allowances for the operational constraints. Any modifications are being closely monitored and subject to appropriate governance.

Government travel restrictions and social distancing measures across the world have required the Company to implement contingency plans and changes to some operational processes to ensure continued uninterrupted service to customers, while minimising the impact on the quality of service provided. These plans involve most staff being able to work from home, including customer contact centre staff. The changes to operational processes that have been implemented have been designed to ensure customer service, data protection and staff well-being risks are at a level accepted by Management.

An out of cycle ORSA was triggered, in accordance with the ORSA Policy. Updates on the ORSA processes are being regularly provided to the Board.

Risk profile

The current process for monitoring the risks, the risk-mitigation techniques in place and the material concentrations of risk to which the business is exposed as a result of COVID-19 for each of the Company's key risk types are set out in this section.

The Company performs sensitivity analyses, stress and scenario testing in order to understand the impact that changes in underlying risk calibrations and correlations of those risks would have on the Company's risk profile and SCR. See section C.7 for details of the methodology employed in sensitivity analysis, the assumptions and limitations in performing these analyses and the results obtained at 31 December 2019.

Underwriting risk

The Company's non-life insurance underwriting exposure in the UK, Ireland and Canada arising from COVID-19, together with mitigants, are as follows:

• Business Interruption: For the significant majority of the Company's business interruption policies, where policy wordings are determined by the Company, cover is based on a specified list of diseases. These policies exclude business interruption due to new and emerging diseases, like COVID-19. Policy wordings clearly identify the diseases covered and also highlight that new and emerging diseases are not covered. Business interruption losses stemming from the current COVID-19 outbreak are therefore not covered under the significant majority of business interruption policies but there is a risk that litigation will be required to provide legal clarity in terms of the events and the cover provided under broker determined business interruption policies in Ireland and Canada where we have agreed there is cover under a specific pandemic risk cover for Canadian dentists. There is a similar risk of litigation being required in these jurisdictions to provide legal clarity on other business interruption policy wordings.

- **Travel Insurance:** The Company is exposed to claims for travel cancellation, disruption and sickness due to COVID-19. However, the Company is only exposed to losses after recoveries have been made from travel providers and agents. Steps have been taken through pricing actions and withdrawal of products and policy options to limit exposure to new business.
- **Other**: The economic disruption and anticipated recession arising from COVID-19 are likely to lead to increased claims across a wide range of policies, including credit, directors and officers and surety covers. There are also likely to be adverse impacts on future premium volumes.

The Company's exposure to underwriting risk is mitigated by its quota share arrangements with AIIL, covering 50% of its own risks and 25% of risks arising in ACI.

Market risk

As a result of the financial market impact of COVID-19 the Company has taken a number of actions to reduce exposure to equity and interest rate risk. Actions include purchasing tactical derivative hedges, asset disposals and reallocations.

Credit risk

As a result of the financial market impact of COVID-19 the Company has taken a number of actions to reduce exposure to credit spread and counterparty default risk. Actions include purchasing tactical derivative hedges, asset disposals and reallocation.

Liquidity risk

To mitigate any potential risk to liquidity if there was a significant further worsening of impacts from the COVID-19 pandemic, the Company has increased liquidity through the selective disposal of assets.

Operational risk

COVID-19 is resulting in increased level of inherent operational risk through enforced remote working, staff absences for sickness and childcare, market volatility and through our outsourcing arrangements. Processes and controls are being adjusted to ensure operational risks remain at an acceptable level.

Valuation for solvency purposes

The COVID-19 pandemic has resulted in declines in global financial markets with a corresponding impact on the valuation of certain financial assets held at fair value within the Company's balance sheet. The pandemic has also resulted in an increase in volatility in financial markets, increasing the valuation uncertainty of assets and liabilities valued using an alternative method for valuation as described in section D.4. The Company has taken a number of actions to reduce exposure to market risk and credit risk and will continue to monitor its balance sheet exposure.

Technical provisions have been prepared based on conditions and best estimate assumptions at 31 December 2019 and have therefore not been adjusted for any impacts of COVID-19. General insurance technical provisions will be impacted as a result of disruption to travel and businesses insured by the Company.

There will be similar impacts on the valuation of financial assets and technical provisions of the Company's material subsidiaries will impact the value of the Company's participations.

The Company and its material subsidiaries review the best estimate assumptions used in the calculation of technical provisions on an ongoing basis and will update them accordingly for the expected impacts of COVID-19. However, given the rapidly evolving nature of the situation, it is not practicable at this stage to quantify the potential valuation impact of the pandemic and related financial market impacts, on the financial assets and technical provisions of the Company.

Capital management

The capital of the Company is monitored on an ongoing basis. At FY19 the Company had strong solvency levels and expects to continue to meet its Solvency Capital Requirements (unaudited). Notwithstanding this, insurance claims arising from the COVID-19 pandemic and the associated volatility in financial markets will most likely have an adverse impact on the Company's own funds and solvency coverage ratio (unaudited). The Company's balance sheet exposure and solvency position is being reviewed on an ongoing basis and actions are being taken to protect the solvency position and further reduce the sensitivity to economic shocks and mitigate insurance risk.